Santech Holdings Limited (STEC) 20-F 18 Oct 23 2023 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jun. 30, 2023 shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Period End Date	Jun. 30, 2023
Entity File Number	001-40238
Entity Registrant Name	Hywin Holdings Ltd.
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	F3, Hywin Financial Centre
Entity Address, Address Line Two	8 Yincheng Mid. Road
Entity Address, Address Line Three	Pudong New District
Entity Address, City or Town	Shanghai
Entity Address, Country	CN
Entity Address, Postal Zip Code	200120
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
ICFR Auditor Attestation Flag	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Marcum Asia CPAs LLP
Auditor Firm ID	5395
Auditor Location	Beijing, China
Entity Central Index Key	0001785680
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Amendment Flag	false
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	F3, Hywin Financial Centre
Entity Address, Address Line Two	8 Yincheng Mid. Road
Entity Address, Address Line Three	Pudong New District
Entity Address, City or Town	Shanghai
Entity Address, Country	CN
Entity Address, Postal Zip Code	200120
City Area Code	+86 21
Local Phone Number	80133992
Contact Personnel Email Address	IR@hywinwealth.com
Contact Personnel Name	Wai LOK
ADS
Document Information [Line Items]
Title of 12(b) Security	American depositary shares
Trading Symbol	HYW
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	8,250,000
Ordinary shares
Document Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value US$0.0001 per share
No Trading Symbol Flag	true
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding	47,750,000

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)
Current assets:
Cash and cash equivalents	¥ 868,908	$ 120,251	¥ 525,136
Restricted cash	76,975	10,653	135,242
Term deposit	28,903	4,000
Accounts receivable, net	415,134	57,452	564,374
Due from related parties			66,103
Deposits, prepayments and other current assets	46,392	6,420	51,204
Contract assets	33,491	4,635
Total current assets	1,469,803	203,411	1,342,059
Property and equipment, net	349,685	48,394	325,112
Long term investment	1,000	138	1,000
Intangible assets, net	98,603	13,646	33,548
Goodwill	257,712	35,666	75,194
Long-term prepayments	9,657	1,336	5,774
Deferred tax assets, net	725	100	725
Operating lease right-of-use assets	186,307	25,784
Total non-current assets	903,689	125,064	441,353
Total Assets	2,373,492	328,475	1,783,412
Current liabilities:
Commission payable	172,456	23,867	83,205
Accounts payable	3,332	461
Advance from customers	39,812	5,510
Investors' deposit	70,934	9,817	132,154
Income tax payable	167,798	23,222	120,151
Due to related parties	38,073	5,269	36,172
Borrowings			2,000
Consideration payable and other payables	433,217	59,954	406,128
Operating lease liabilities, current	83,573	11,566
Total current liabilities	1,009,195	139,666	779,810
Commission payable-long term	526	73	1,289
Net deferred tax liabilities	20,028	2,772	3,400
Operating lease liabilities, non-current	100,521	13,911
Total non-current liabilities	121,075	16,756	4,689
Total Liabilities	1,130,270	156,422	784,499
Mezzanine equity
Redeemable noncontrolling interest	30,600	4,235	30,600
Total Mezzanine equity	30,600	4,235	30,600
Equity:
Ordinary shares (US$0.0001 par value; authorized 500,000,000 shares; issued and outstanding 56,000,000* shares as of June 30, 2022 and 2023, respectively)	36	5	36
Additional paid-in capital	515,665	71,364	510,390
Statutory reserves	128,297	17,755	100,926
Retained earnings	451,013	62,417	348,503
Accumulated other comprehensive income	16,680	2,309	8,458
Total equity attributable to the shareholders of Hywin Holdings Ltd.	1,111,691	153,850	968,313
Noncontrolling interests	100,931	13,968
Total equity	1,212,622	167,818	968,313
Total Liabilities, Mezzanine equity, and equity	2,373,492	328,475	1,783,412
Related Party
Current assets:
Due from related parties			66,103
Current liabilities:
Due to related parties	¥ 38,073	$ 5,269	¥ 36,172

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
CONSOLIDATED BALANCE SHEETS
Ordinary shares, par value	$ 0.0001	$ 0.0001
Ordinary shares, authorized	500,000,000	500,000,000
Ordinary shares, issued shares	56,000,000	56,000,000	56,000,000	50,000,000
Ordinary shares, outstanding shares	56,000,000	56,000,000

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥) ¥ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 CNY (¥) ¥ / shares shares	Jun. 30, 2021 CNY (¥) ¥ / shares shares
Net revenues
Total net revenues	¥ 2,091,757	$ 301,280	¥ 1,942,113	¥ 1,834,422
Operating cost and expenses
Compensation and benefits	1,156,381	166,556	1,050,077	1,003,061
Health management costs	74,476	10,727	4,287
Share-based compensation expense	5,207	750	7,340	21,947
Sales and marketing expenses	318,465	45,869	311,773	326,879
General and administrative expenses	302,221	43,530	241,946	200,929
Impairment loss on goodwill	35,412	5,100	0	0
Impairment loss on intangible assets	2,210	318	0	0
Total operating cost and expenses	1,894,372	272,850	1,615,423	1,552,816
Income from operations	197,385	28,430	326,690	281,606
Other income/(expenses)
Interest income, net	1,348	194	1,498	1,537
Other income/(expenses), net	(7,083)	(1,020)	(3,741)	12,608
Total other income/(expenses), net	(5,735)	(826)	(2,243)	14,145
Income before income tax expense	191,650	27,604	324,447	295,751
Income tax expense	(71,380)	(10,281)	(88,578)	(88,094)
Net income	120,270	17,323	235,869	207,657
Less: net loss attributable to non-controlling interests	(9,611)	(1,384)
Net income attributable to shareholders of Hywin Holdings Ltd.	129,881	18,707	235,869	207,657
Foreign currency translation gain	8,222	1,184	4,177	10,542
Comprehensive Income	128,492	18,507	240,046	218,199
Less: Comprehensive Loss attributable to non-controlling interests	(9,611)	(1,384)
Comprehensive Income attributable to shareholders of Hywin Holdings Ltd.	¥ 138,103	$ 19,891	¥ 240,046	¥ 218,199
Earnings per share
Earnings per share - Basic | (per share)	¥ 2.32	$ 0.33	¥ 4.21	¥ 4.03
Earnings per share - diluted | (per share)	¥ 2.24	$ 0.32	¥ 4.07	¥ 3.88
Weighted average number outstanding:
Weighted average number outstanding - Basic	56,000	56,000	56,000	51,528
Weighted average number outstanding - Diluted	57,972	57,972	57,980	53,520
Wealth management [Member]
Net revenues
Total net revenues	¥ 1,949,410	$ 280,777	¥ 1,899,573	¥ 1,795,552
Assets Management
Net revenues
Total net revenues	32,562	4,690	19,476	14,942
Health Management [Member]
Net revenues
Total net revenues	86,464	12,454	422
Product and Service, Other [Member]
Net revenues
Total net revenues	¥ 23,321	$ 3,359	¥ 22,642	¥ 23,928
Ordinary shares
Earnings per share
Earnings per share - Basic | (per share)	¥ 2.32	$ 0.33	¥ 4.21	¥ 4.03
Earnings per share - diluted | (per share)	¥ 2.24	$ 0.32	¥ 4.07	¥ 3.88
Weighted average number outstanding:
Weighted average number outstanding - Basic	56,000,000	56,000,000	56,000,000	51,578,082
Weighted average number outstanding - Diluted	57,972,472	57,972,472	57,979,504	53,547,163
ADS
Earnings per share
Earnings per share - Basic | (per share)	¥ 4.64	$ 0.67	¥ 8.42	¥ 8.05
Earnings per share - diluted | (per share)	¥ 4.48	$ 0.65	¥ 8.14	¥ 7.76
Weighted average number outstanding:
Weighted average number outstanding - Basic	28,000,000	28,000,000	28,000,000	25,789,041
Weighted average number outstanding - Diluted	28,986,236	28,986,236	28,989,752	26,773,582
Third parties
Net revenues
Total net revenues	¥ 2,090,078	$ 301,039	¥ 1,937,614	¥ 1,831,278
Third parties | Wealth management [Member]
Net revenues
Total net revenues	1,947,731	280,536	1,895,074	1,792,408
Third parties | Assets Management
Net revenues
Total net revenues	32,562	4,690	19,476	14,942
Third parties | Health Management [Member]
Net revenues
Total net revenues	86,464	12,454	422
Third parties | Product and Service, Other [Member]
Net revenues
Total net revenues	23,321	3,359	22,642	23,928
Related parties
Net revenues
Total net revenues	1,679	241	4,499	3,144
Related parties | Wealth management [Member]
Net revenues
Total net revenues	¥ 1,679	$ 241	¥ 4,499	¥ 3,144

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY ¥ in Thousands, $ in Thousands		Total Shareholders' equity CNY (¥)	Total Shareholders' equity USD ($)	Ordinary shares CNY (¥) shares		Ordinary shares USD ($) shares		Additional paid-in capital CNY (¥)	Additional paid-in capital USD ($)	Statutory reserves CNY (¥)	Statutory reserves USD ($)	(Accumulated deficit)/ Retained earnings CNY (¥)	(Accumulated deficit)/ Retained earnings USD ($)	Accumulated other comprehensive (loss)/income CNY (¥)	Accumulated other comprehensive (loss)/income USD ($)	Noncontrolling interest CNY (¥)	Noncontrolling interest USD ($)	CNY (¥) shares	USD ($) shares
Balance at the beginning at Jun. 30, 2020				¥ 34				¥ 500,581		¥ 52,959		¥ (47,056)		¥ (6,261)				¥ 500,257
Balance at the beginning (in shares) at Jun. 30, 2020 | shares				50,000,000	[1]	50,000,000	[1]											50,000,000	50,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for the year												207,657						¥ 207,657
Issuance of shares through IPO				¥ 2				180,675										180,677
Issuance of shares through IPO (in shares) | shares	[1]			6,000,000		6,000,000
IPO related expenses recognized in equity								(10,082)										(10,082)
Establishment of subsidiaries								4,929										4,929
Share-based compensation recognized in equity								21,947										21,947
Capital reduction of a consolidated VIE								(195,000)										(195,000)
Appropriation of statutory reserves										25,004		(25,004)
Foreign currency translation adjustment														10,542				10,542
Balance at the end at Jun. 30, 2021				¥ 36				503,050		77,963		135,597		4,281				¥ 720,927
Balance at the end (in shares) at Jun. 30, 2021 | shares				56,000,000	[1]	56,000,000	[1]											56,000,000	56,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for the year												235,869						¥ 235,869
Share-based compensation recognized in equity								7,340										7,340
Appropriation of statutory reserves										22,963		(22,963)
Foreign currency translation adjustment														4,177				4,177
Balance at the end at Jun. 30, 2022		¥ 968,313		¥ 36				510,390		100,926		348,503		8,458				¥ 968,313
Balance at the end (in shares) at Jun. 30, 2022 | shares				56,000,000	[1]	56,000,000	[1]											56,000,000	56,000,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income for the year		129,881										129,881				¥ (9,611)		¥ 129,881	$ 18,707
Net income for the year																		120,270
Share-based compensation recognized in equity		5,207						5,207										5,207
Appropriation of statutory reserves										27,371		(27,371)
Foreign currency translation adjustment		8,222												8,222				8,222	1,184
Acquisition of Life Infinity and SCHMC (Note 4)																107,042		107,042
Contribution from noncontrolling shareholders (Note 13)																3,500		3,500
Contribution from a shareholder (Note 13)		68						68										68
Balance at the end at Jun. 30, 2023		¥ 1,111,691	$ 153,850	¥ 36		$ 5		¥ 515,665	$ 71,364	¥ 128,297	$ 17,755	¥ 451,013	$ 62,417	¥ 16,680	$ 2,309	¥ 100,931	$ 13,968	¥ 1,212,622	$ 167,818
Balance at the end (in shares) at Jun. 30, 2023 | shares				56,000,000	[1]	56,000,000	[1]											56,000,000	56,000,000
[1]The shares are presented on a retroactive basis to reflect the nominal share issuance (Note 13).

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Cash flows from operating activities
Net income	¥ 120,270	$ 17,323	¥ 235,869	¥ 207,657
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	54,270	7,817	28,327	25,594
Non-cash operating lease expense	85,809	12,359
Share-based compensation expenses	5,207	750	7,340	21,947
Impairment loss on goodwill	35,412	5,100	0	0
Impairment loss on intangible assets	2,210	318
Loss from disposal of long-term assets	83	12	22	81
Changes in deferred taxes	(1,841)	(265)	118	1,727
Changes in operating assets and liabilities
Accounts receivable	156,991	22,612	30,165	(190,368)
Contract assets	(33,491)	(4,824)
Due from related parties	66,103	9,521	60,000	(1,579)
Deposits, prepayments and other current assets	96,229	13,860	1,757	(15,923)
Commission payable	89,251	12,855	(45,380)	42,337
Commission payable-long term	(763)	(110)	(8,791)	(8,241)
Accounts payable	(40,990)	(5,904)
Advance from customers	(21,594)	(3,110)
Long-term prepayments			1,653
Investors' deposit	(61,220)	(8,818)	(116,123)	174,015
Income tax payable	47,647	6,863	3,254	1,465
Operating lease liabilities	(77,887)	(11,218)
Other payables and accrued liabilities	691	99	30,467	75,049
Due to related parties	1,901	274	11,373	272
Commitments and contingencies	1,034	149	(1,300)
Net cash provided by operating activities	525,322	75,663	238,751	334,033
Cash flows from investing activities
Payment for office equipment, furniture and leasehold improvements	(19,882)	(2,864)	(8,418)	(11,945)
Payment for intangible assets	(1,604)	(231)	(3,603)	(2,938)
Proceeds from disposal of long-term assets	28	4	27	252
Purchases of equity investments			(1,000)
Purchases of term deposit	(28,903)	(4,163)
Payment of consideration payable	(15,300)	(2,204)
Acquisition of a subsidiary, net of cash acquired (Note 4)	(183,004)	(26,358)	(41,464)
Acquisition of buildings and properties			(232,039)
Net cash used in investing activities	(248,665)	(35,816)	(286,497)	(14,631)
Cash flows from financing activities
Proceeds from issuance of ordinary shares from IPO				180,677
Contributions from a shareholder and noncontrolling shareholders	3,568	514		4,929
Repayment of loans borrowed from third parties	(2,000)	(288)	(1,000)
Net cash provided by/(used in) financing activities	1,568	226	(1,000)	185,606
Effect of exchange rate changes	7,280	(7,565)	3,814	11,917
Net increase/ (decrease) in cash, cash equivalents and restricted cash	285,505	32,508	(44,932)	516,925
Cash, cash equivalents, and restricted cash at beginning of the year	660,378	98,396	705,310
Cash, cash equivalents, and restricted cash at end of the year	945,883	130,904	660,378	705,310
Reconciliation to amounts on consolidated balances sheets
Cash and cash equivalents	868,908	120,251	525,136	439,287
Restricted cash	76,975	10,653	135,242	266,023
Total cash, cash equivalents, and restricted cash	945,883		660,378	705,310
Supplemental disclosure of cash flow information
Income taxes paid	27,389	3,945	84,983	84,871
Non-cash transactions:
Net off consideration from capital reduction of a VIE with the amount due from the controlling shareholder of the VIE				¥ 195,000
Consideration payable related to business acquisition of a subsidiary			15,300
Liabilities assumed related to acquisition of buildings and properties			¥ 73,950
Effect on operating assets upon the adoption of ASU 2016-13 on July 1, 2022	204,296	29,425
Right-of-use assets obtained in exchange for lease obligations, net of decrease of right-of-use assets for early terminations	48,572	6,996
Transfer of prepayment of other liabilities to lease liabilities	¥ 10,135	$ 1,460

Organization

Organization	12 Months Ended
	Jun. 30, 2023
Organization
Organization	1. Organization Hywin Holdings Ltd. (the “Company”), was incorporated in the Cayman Islands on July 19, 2019. The Company, through its subsidiaries, consolidated variable interest entities (the “VIEs”) and the VIEs’ subsidiaries (collectively, the “Group”), is primarily engaged in providing wealth management service, insurance brokerage service and asset management service in the People’s Republic of China (the “PRC” or “China”). Due to that foreign ownership of certain parts of the Group’s businesses is subject to restrictions under current PRC laws and regulations, the Company conducts its primary business operations through its VIEs and subsidiaries of the VIEs. The Company is ultimately controlled by Mr. HAN Hongwei (the “Founder”) since its establishment. On March 26, 2021, the Company completed its initial public offering (“IPO”) of 3,000,000 ADSs at US$10.00 per ADS on NASDAQ. Each ADS represents two ordinary shares of the Company. As of June 30, 2023, the detailed information of the Group’s major consolidated subsidiaries, VIEs and significant VIEs’ subsidiaries are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Date of ​ Percentage of ​ Place of ​ ​ Name of the entity incorporation ownership incorporation Principle business activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ ​ ​ ​ ​ ​ Hywin Wealth Global Limited ​ July 26, 2019 100 % BVI Investment holding Hywin Wealth International Limited ​ August 20, 2019 100 % Hong Kong Investment holding Hywin Enterprise Management Consulting (Shanghai) Co., Ltd. ​ September 26, 2019 100 % PRC Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Variable Interest Entities (“VIEs”) ​ Hywin Wealth Management Co., Ltd. ​ November 2, 2006 100 % PRC Investment holding and provision of wealth management service Shanghai Hywin Network Technology Co., Ltd. ​ March 31, 2017 100 % PRC Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Shenzhen Panying Asset Management Co., Ltd. ​ May 23, 2014 100 % PRC Provision of asset management service ​ ​ ​ ​ ​ ​ ​ ​ ​ VIEs’ significant subsidiaries ​ Hywin Fund Distribution Co., Ltd. ​ April 17, 2013 100 % PRC Provision of wealth management service Shanghai Ziji Information Technology Co., Ltd. ​ November 24, 2017 100 % PRC Provision of information technology support Haiyin Wealth Management (Hong Kong) Limited ​ May 3, 2016 100 % Hong Kong Investment holding and provision of insurance brokerage service Haiyin Insurance (Hong Kong) Co., Limited ​ August 24, 2016 100 % Hong Kong Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Hywin International Insurance Broker Limited ​ March 23, 2006 100 % Hong Kong Provision of insurance brokerage service Haiyin International Asset Management Limited ​ September 15, 2016 100 % Hong Kong Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Hywin Asset Management (Hong Kong) Limited ​ January 9, 2013 100 % Hong Kong Provision of wealth management and asset management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Yulan Real Estate Co., Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Suxiao Real Property Co., Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Danxiao Real Property Co. Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Biyu Real Property Co., Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Hywin Health Management (Shanghai) Co., Ltd ​ September 15,2021 ​ 100% ​ PRC ​ Investment holding and provision of health management service ​ ​ ​ ​ ​ ​ ​ ​ ​ Grand Doctor Medical Co., Ltd. ​ January 27, 2022 ​ 65.3% ​ PRC ​ Provision of health management service ​ ​ ​ ​ ​ ​ ​ ​ ​ Beijing iLife 3 Technology Co., Ltd. ​ August 25, 2022 ​ 63.39% ​ PRC ​ Provision of health management service ​ ​ ​ ​ ​ ​ ​ ​ ​ Sincerity and Compassion Health Management Center ​ September 1, 2022 ​ 65% ​ PRC ​ Provision of health management service ​ The Group primarily conducts its operations in the PRC. In January 2020, an outbreak of a novel coronavirus (COVID-19) surfaced in Wuhan City, Hubei province of the PRC, and spread all over the country during the first fiscal quarter of 2020. The outbreak caused the Chinese government to require businesses to close, people to quarantine, and also to restrict certain travel within the country until April 2020. The spread of COVID-19 has resulted in the World Health Organization declaring the outbreak of COVID-19 as a global pandemic. As of the date hereof, the outbreak of COVID-19 in China during the year ended June 30, 2023 has not caused a material negative impact on the Group’s overall business operations, financial condition, liquidity, results of operations and prospects. The extent to which COVID-19 impacts the business and financial results of the Group depends on future developments, which are uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and actions to contain COVID-19 or mitigate its impact, among others. Although the Chinese government have declared the COVID-19 outbreak largely under control within its border, the Group will continue to assess its financial impacts for the future fiscal year. There can be no assurance that this assessment will enable the Group to avoid part or all of any adverse impact from the spread of COVID-19 or its consequences, including downturns in business sentiment generally or in the Group’s sector in particular.

Variable Interest Entities

Variable Interest Entities	12 Months Ended
	Jun. 30, 2023
Variable Interest Entities
Variable Interest Entities	2. Variable Interest Entities To satisfy PRC laws and regulations, the Company conducts certain business in the PRC through its VIEs. The significant terms of the VIE Agreements are summarized below: Exclusive Technical Consultation and Service Agreements: Pursuant to the Exclusive Technical Consultation and Service Agreement between Hywin Enterprise Management Consulting (Shanghai) Co., Ltd. (Hywin Consulting) and each of the VIEs, Hywin Consulting has the exclusive right to provide consultation and services to the VIEs in its businesses and operations, human resources, technology and intellectual property rights, in return for fee equal to 100% of the consolidated net income of each of the VIEs. Without Hywin Consulting’s prior written consent, the VIEs shall not, directly and indirectly, obtain the same or similar services as provided under this agreement from any third party, or enter into any similar agreement with any third party. Hywin Consulting has the right to determine the service fee charged to each of the VIEs under the respective agreement by considering, among other things, the complexity of the services, the time spent by employees of Hywin Consulting to provide the services, content and commercial value of the service provided, as well as the benchmark price of similar services in the market. Hywin Consulting exclusively owns any intellectual property rights arising from the performance of this Exclusive Technical Consultation and Service Agreement. The Exclusive Technical Consultation and Services Agreements remain in effect for 20 years from the date when the agreements were signed. The Exclusive Technical Consultation and Service Agreements can be extended only if Hywin Consulting gives its written consent of the extension before the expiration of the agreements and the VIEs will agree to the extension without reserve. Equity Pledge Agreements: Pursuant to a series of Equity Pledge Agreements among Hywin Consulting, each of the VIEs and each of their respective shareholders, shareholders of the VIEs shall pledge all of their equity interests in the respective VIEs to Hywin Consulting to guarantee the VIEs’ performance of relevant obligations and indebtedness under each of their respective Exclusive Technical Consultation and Service Agreement and other control agreements (“Control Agreement”). In addition, all the shareholders of the VIEs has completed on September 25, 2020 the registration of the equity pledge under the Equity Pledge Agreements with the competent local authority in the PRC. If the VIEs or any of its shareholders breach its obligation under the Control Agreement, Hywin Consulting, as pledgee, will be entitled to certain rights, including the right to dispose the pledged equity interests in order to recover these breached amounts. The respective Equity Pledge Agreements will be continuously valid until all of the shareholders of that VIE are no longer its shareholders or until that VIE’s obligations under the Control Agreements are satisfied. Equity Option Agreements: Pursuant to a series of Equity Option Agreements among Hywin Consulting, each of the VIEs and each of their respective shareholders, Hywin Consulting has the exclusive right to require all the shareholders of the respective VIEs to fulfill and complete all approval and registration procedures required under the PRC laws for Hywin Consulting to purchase, or designate one or more persons to purchase, equity interests owned by the VIEs’ shareholders in the respective VIEs, once or at multiple times at any time in part or in whole at Hywin Consulting’s sole and absolute discretion. The purchase price will be the lowest price allowed by the PRC laws. The respective Equity Option Agreements will remain effective until all the equity interest owned by each shareholder of that VIE has been legally transferred to Hywin Consulting or its designee(s). Voting Right Proxy and Financial Support Agreements: Pursuant to the Voting Rights Proxy and Financial Supporting Agreements among Hywin Consulting, each of the VIEs and each of their respective shareholders, each shareholder of the VIEs irrevocably appointed Hywin Consulting or Hywin Consulting’s designee to exercise all his/her/its rights as a shareholder of the respective VIEs under the Articles of Association of that VIE, including but not limited to the power to exercise all shareholders’ voting rights with respect to all matters to be discussed and voted in the shareholders’ meeting of that VIE. In consideration of the foregoing grant of voting rights by all of the shareholders of the VIEs, Hywin Consulting agrees to arrange for funds to be provided as necessary to the VIEs in connection with their respective business needs. In the case that any of VIEs is unable to repay the financial support, the VIEs should have no repayment obligation. The term of the Voting Rights Proxy and Financial Support Agreements is 20 years. As a result of these VIE Agreements, the Company through its wholly-owned subsidiary, Hywin Consulting, was granted with unconstrained decision making rights and power over key strategic and operational functions that would significantly impact the VIEs’ economic performance. As a result of the Exclusive Technical Consultation and Service Agreements, the Equity Pledge Agreements and the Equity Option Agreements, the Company will bear all of the VIEs’ operating costs in exchange for the 100% net income of the VIEs. Under these agreements, the Company has the absolute and exclusive right to enjoy economic benefits similar to equity ownership through the VIE Agreements with the VIEs and their shareholders. Risks in relation to the VIE structure The Company believes that its current contractual arrangements with the VIEs and their respective shareholders are valid, binding and enforceable. However, there are uncertainties and risks in relation to the Company’s VIE Structure. On March 15, 2019, the National People’s Congress of the PRC approved the Foreign Investment Law, which came into effect on January 1, 2020, replacing three existing laws regulating foreign investment in China, namely, the Sino-foreign Equity Joint Venture Enterprise Law, the Sino-foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-invested Enterprise Law, as well as their implementation rules and ancillary regulations. The Foreign Investment Law embodies an expected PRC regulatory trend to rationalize its foreign investment regulatory regime in line with prevailing international practice and the legislative efforts to unify the corporate legal requirements for both foreign and domestic investments. However, since it is relatively new, uncertainties still exist in relation to its interpretation and implementation. While it does not explicitly classify contractual arrangements as a form of foreign investment, there is no assurance that foreign investment via contractual arrangement would not be interpreted as a type of indirect foreign investment activity under the definition in the future. In addition, the definition contains a catch-all provision which includes investments made by foreign investors through means stipulated in the laws or administrative regulations or other methods prescribed by the State Council. Therefore, it still leaves leeway for future laws, administrative regulations or provisions promulgated by the State Council to provide for contractual arrangements as a form of foreign investment. In any of these cases, it will be uncertain whether the Company’s contractual arrangements will be deemed to be in violation of the market access requirements for foreign investment under the PRC laws and regulations. Furthermore, if future laws, administrative regulations or provisions prescribed by the State Council mandate further actions to be taken by companies with respect to existing contractual arrangements, the Company may face substantial uncertainties as to whether it can complete such actions in a timely manner, or at all. Failure to take timely and appropriate measures in response to any of these or similar regulatory compliance changes could materially and adversely affect the Company’s current corporate structure, corporate governance and business operations. In addition, these contractual arrangements may not be as effective in providing the Company with control over the VIEs as direct ownership. Due to its VIE structure, the Company has to rely on contractual rights to effect control and management of the VIEs, which exposes it to the risk of potential breach of contract by the shareholders of the VIEs for a number of reasons. For example, their interests as shareholders of the VIEs and the interests of the Company may conflict, and the Company may fail to resolve such conflicts; the shareholders may believe that breaching the contracts will lead to greater economic benefit for them; or the shareholders may otherwise act in bad faith. If any of the foregoing were to happen, the Company may have to rely on legal or arbitral proceedings to enforce its contractual rights, including specific performance or injunctive relief, and claiming damages. Such arbitral and legal proceedings may cost substantial financial and other resources, and result in a disruption of its business, and the Company cannot assure that the outcome will be in its favor. In addition, as all of these contractual arrangements are governed by PRC law and provide for the resolution of disputes through either arbitration or litigation in the PRC, they would be interpreted in accordance with PRC law and any disputes would be resolved in accordance with PRC legal procedures. The legal environment in the PRC is not as developed as in other jurisdictions, such as the United States. As a result, uncertainties in the PRC legal system could further limit the Company’s ability to enforce these contractual arrangements. Furthermore, these contracts may not be enforceable in China if PRC government authorities or courts take a view that such contracts contravene PRC laws and regulations or are otherwise not enforceable for public policy reasons. In the event that the Company is unable to enforce any of these agreements, the Company would not be able to exert effective control over the affected VIEs and consequently, the results of operations, assets and liabilities of the affected VIEs and their subsidiaries would not be included in the Company’s consolidated financial statements. If such were the case, the Company’s cash flows, financial position and operating performance would be materially adversely affected. Total assets and liabilities presented on the Group’s consolidated balance sheets, net revenues, operating cost and expenses, and net income presented on the Group’s consolidated statements of income and comprehensive income, as well as the cash flows from operating, investing and financing activities presented on the Group’s consolidated statements of cash flows are substantially the financial position, result of operations and cash flows of the Company’s consolidated VIEs. The following balances and amounts of the VIEs were included in the Group’s consolidated financial statements as of June 30, 2022 and 2023 or for the years ended June 30, 2021, 2022 and 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ (RMB) ​ (RMB) ​ (US$) ​ ​ ​ ​ ​ ​ ​ Total Assets 1,609,296 ​ 2,243,526 ​ 310,488 Total liabilities 784,499 ​ 1,183,705 ​ 163,816 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ ​ (RMB) ​ (RMB) ​ (RMB) ​ (US$) ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenues 1,834,422 ​ 1,942,113 ​ 2,091,757 ​ 301,280 Net income 207,662 ​ 239,445 ​ 131,222 ​ 18,900 Cash flow provided by operating activities 334,038 ​ 242,326 ​ 525,229 ​ 75,650 Cash flow used in investing activities (14,631) ​ (286,497) ​ (201,099) ​ (28,965) Cash flow provided by/(used in) financing activities 4,895 ​ (1,000) ​ 1,568 ​ 226 ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies a) Basis of presentation The Group’s consolidated financial statements are prepared and presented in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). b) Principles of consolidation and non-controlling interest The Group’s consolidated financial statements include the accounts of the Company, its subsidiaries and its consolidated VIEs, of which the Company is the primary beneficiary, from the dates they were acquired or incorporated. All inter-company transactions and balances have been eliminated upon consolidation. For the Group’s majority-owned subsidiaries, VIEs and subsidiaries of VIEs, a non-controlling interest is recognized to reflect the portion of their equity which is not attributable, directly or indirectly, to the Group. Consolidated net income on the consolidated statements of income and comprehensive income includes the net loss attributable to non-controlling interests. The cumulative results of operations attributable to non-controlling interests, are recorded as non-controlling interests on the Group’s consolidated balance sheets. c) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of these consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Group continually evaluates these estimates and assumptions based on the most recently available information, historical experience and various other assumptions that the Group believes to be reasonable under the circumstances. Significant accounting estimates reflected in the Group’s consolidated financial statements include but are not limited to estimates and judgments applied in determination of allowance for doubtful receivables and loans, impairment losses for long-lived assets, impairment of goodwill and indefinite-lived intangibles, valuation allowance for deferred tax assets, the purchase price allocation in acquisitions and the renewal compensation for insurance. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from those estimates. d) Foreign currency translation and transactions The Group’s reporting currency is Renminbi (“RMB”). The Group’s operations are principally conducted through its subsidiaries and VIEs located in the PRC where RMB is the functional currency. For those subsidiaries and VIEs which are not located in mainland PRC and have the functional currency other than RMB, the financial statements are translated from their respective functional currencies into RMB. Assets and liabilities are translated using the exchange rate at each balance sheet date. Revenue and expenses are translated using average rates prevailing during each reporting period, and shareholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income/(loss) in shareholders’ equity. Translations of amounts from RMB into US$ are solely for the convenience of the reader and were calculated at the rate of US$1.00 = RMB 7.2258 on June 30, 2023 for balance sheet items, except equity, and US$1.00 = RMB 6.9429 for items in the statement of operation and comprehensive income, and statement of cash flow, representing the certificated exchange rate published by the People’s Bank of China. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on June 30, 2023, or at any other rate. e) Cash and cash equivalents Cash and cash equivalents consist of bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. f) Restricted cash Restricted cash mainly represents the investors’ uninvested cash balances temporarily deposited in the Group’s bank accounts. These cash balances were under the custody and supervision of the designated financial institution as required by the China Securities Regulatory Commission (“CSRC”), for the purpose of preventing misuse of investors’ funds. g) Term deposit Term deposit represent demand deposits placed with banks with original maturities of more than three months but less than one year. Interest earned is recorded as interest income in the consolidated statements of comprehensive income during the periods. h) Accounts receivable, net The Group records accounts receivable at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Group’s best estimate of the amount of probable credit losses in the Group’s existing accounts receivable. The Group determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The aging schedule of the accounts receivable is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Less than 3 months 450,326 ​ 404,295 ​ 55,952 More than 3 months and less than 1 year 111,049 ​ 7,468 ​ 1,033 More than 1 year 2,999 ​ 3,371 ​ 467 Total 564,374 ​ 415,134 ​ 57,452 ​ The roll forward schedule of accounts receivable is as follows: ​ ​ ​ ​ ​ ​ ​ ​ Amount ​ RMB US$ Balance as of June 30, 2021 594,061 ​ 91,958 Revenue (including VAT) 2,055,534 ​ 318,352 Collections (2,085,221) ​ (326,218) Balance as of June 30, 2022 564,374 ​ 84,092 Acquisition of Life Infinity & SCHMC ​ 7,715 ​ 1,125 Revenue (including VAT) 2,197,657 ​ 316,533 Collections (2,354,648) ​ (344,298) Balance as of June 30, 2023 415,134 ​ 57,452 ​ As of June 30, 2022 and 2023, the Group recorded nil and nil allowances for doubtful accounts against its accounts receivable, respectively. i) Property and equipment, net The Group’s property and equipment are recorded at cost less accumulated depreciation and impairment loss, if any. Depreciation is calculated on the straight-line method after taking into account their respective estimated residual values over the following estimated useful lives: ​ ​ ​ ​ Real estate property 14 years Leasehold improvements Shorter of the remaining lease terms and estimated useful lives Electronic equipment 3- 16 Furniture, fixture and other equipment ​ 3- 14 Motor Vehicles 5 years ​ When property and equipment are retired or otherwise disposed of, resulting gain or loss is included in net income in the period of disposition. For the years ended June 30, 2021, 2022 and 2023, the Group recognized a loss of RMB81, RMB22 and RMB83 (US$12) from disposal of furniture, fixture and equipment, respectively, which were included in the Group’s other expenses. j) Intangible assets, net The Group’s intangible assets primarily consisted of software purchased from third-party suppliers, trademark, internet hospital license, customer relationship, Private Investment Fund Manager Certificate in PRC (“PRC private investment fund manager certificate”), Hong Kong Securities and Futures Commission financial licenses (“HKSFC financial licenses”), Membership of Hong Kong Professional Insurance Brokerage Association (“HK insurance brokerage license”) and others obtained through various business combination transactions. Estimated useful lives of intangible assets are as following: ​ ​ ​ ​ Software 3 Trademark 7 10 Customer relationship 10 years License indefinite life ​ Software is initially recorded at historic acquisition cost and amortized on a straight-line basis over the estimated useful lives of 3 to 5 years Trademark, internet hospital license and customer relationship acquired through the acquisition of Grand Doctor Medical Co., Ltd., Beijing iLife 3 Technology Co., Ltd. and Sincerity and Compassion Health Management Center were estimated by management based on the fair value of assets acquired. Amortization of trademark is recorded on the straight-line method based on the estimated useful lives which is 7-10 years. Internet hospital license is determined to have an indefinite life and it should not be amortized until its useful life is determined to be no longer indefinite. Amortization of customer relationship is recorded on the straight-line method based on the estimated useful lives which is 10 years. PRC private investment fund manager certificate, HKSFC financial licenses and HK insurance brokerage license acquired through the acquisition of Shenzhen Panying, Hywin Asset Management (Hong Kong) Limited and Hywin International Insurance Broker Limited, respectively, were initially recorded at cost, as the assets acquired and liabilities assumed in the respective transactions did not constitute a business, and the transactions were accounted for as asset acquisitions. PRC private investment fund manager certificate, HKSFC financial licenses and HK insurance brokerage license were determined to have an indefinite useful life. As a result, these intangible assets should not be amortized until its useful life is determined to be no longer indefinite. If an intangible asset that is not being amortized is subsequently determined to have a finite useful life, the asset will be tested for impairment and then be amortized prospectively over its estimated remaining useful life and accounted for in the same way as intangible assets subject to amortization. k) Impairment of long-lived assets All long-lived assets, which include tangible long-lived assets and intangible long-lived assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by the assets. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount of the asset and its fair value. For the years ended June 30, 2021, 2022 and 2023, the Group recognized impairment of long-lived assets of nil, nil and RMB2,210 respectively. There were four reporting units of the Group: (1) the wealth unit, (2) Grand Doctor Medical Co., Ltd. (Grand Doctor) acquired on January 27, 2022, (3) Beijing iLife 3 Technology Co., Ltd. (Life Infinity) acquired on August 25, 2022, (4) Sincerity and Compassion Health Management Center (“SCHMC”) acquired on September 1, 2022. Impairment recorded for the year ended June 30, 2023 represented the amount by which the carrying value of the reporting unit of Grand Doctor exceeds their fair value, based on an annual impairment assessment. There were no impairments in other reporting units. l) Goodwill Goodwill represents the excess of the purchase consideration over the acquisition date amounts of the identifiable tangible and intangible assets acquired and liabilities assumed from the acquired entity as a result of the Company’s acquisitions of interests in its subsidiaries. Goodwill is not amortized but is tested for impairment on an annual basis at each balance sheet date on June 30, or more frequently if events or changes in circumstances indicate that it might be impaired. m) Impairment of goodwill and indefinite-lived intangible assets In accordance with ASC 350, the Company may first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. In the qualitative assessment, the Company considers factors such as macroeconomic conditions, industry and market considerations, overall financial performance of the reporting unit, and other specific information related to the operations, business plans and strategies of the reporting unit, including consideration of the impact of the COVID-19 pandemic. Based on the qualitative assessment, if it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the quantitative impairment test is performed. The Company may also bypass the qualitative assessment and proceed directly to perform the quantitative impairment test. The Company adopted ASU 2017-04, from July 1, 2021, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”. After adopting this guidance, the Company performs the quantitative impairment test by comparing the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. If the carrying amount of a reporting unit exceeds its fair value, the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized as impairment. Application of a goodwill impairment test requires significant management judgment, including the identification of reporting units, allocation of assets, liabilities and goodwill to reporting units, and determination of the fair value of each reporting unit. For the years ended June 30, 2021, 2022 and 2023, the Group recognized impairment of goodwill of nil, nil and RMB35,412 respectively. Impairment recorded in 2023 represents the amount by which the carrying value of the reporting unit of Grand Doctor exceeds their fair value, based on an annual goodwill impairment assessment. There were no impairments in other reporting units. An intangible asset that is not subject to amortization shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Based on the qualitative assessment, if it is more likely than not that the fair value of an indefinite-lived intangible asset is less than the carrying value, a quantitative test to measure the amount of impairment must be performed. The quantitative impairment test compares the fair value of the asset with the carrying amount. If the carrying amount exceeds the fair value, then an impairment loss equal to that excess is recorded. For the years ended June 30, 2021, 2022 and 2023, there were no impairment recognized on indefinite-lived intangible assets. n) Leases The Company determines if an arrangement is a lease at inception. Leases that transfer substantially all of the benefits and risks incidental to the ownership of assets are accounted for as finance leases as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases. The Company has no significant finance leases. The Company adopted Accounting Standard Update (“ASU”) 2016-02, “Leases (Topic 842)” from July 1, 2022. The Company recognizes lease liabilities and corresponding right-of-use assets on the balance sheet for leases. Operating lease right-of-use assets and operating lease liabilities are initially recognized based on the present value of future lease payments at lease commencement. The operating lease right-of-use asset also includes any lease payments made prior to lease commencement and the initial direct costs incurred by the lessee and is recorded net of any lease incentives received. As the interest rates implicit in most of the leases are not readily determinable, the Company uses the incremental borrowing rates based on the information available at lease commencement to determine the present value of the future lease payments. Operating lease expenses are recognized on a straight-line basis over the term of the lease. The Company elected not to recognize short-term leases with an initial lease term of twelve months or less. o) Fair value of financial instruments The Group’s financial instruments primarily consist of cash and cash equivalents, restricted cash, term deposit, accounts receivable, short-term loan receivables and due from related parties. The carrying values of these financial instrument approximate fair values due to their short maturities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Group evaluates its hierarchy disclosures each quarter. p) Investors’ Deposit The balance represents the investors’ uninvested cash balances temporarily deposited in the Groups bank account. These deposits were under the custody and supervision of the designated financial institution as required by CSRC, for the purpose of preventing misuse of investors’ funds. q) Business combination Business combinations are recorded using the acquisition method of accounting and, accordingly, the acquired assets and liabilities are recorded at their fair value at the date of acquisition. Any excess of acquisition consideration over the fair value of the acquired assets and liabilities, including identifiable intangible assets, is recorded as goodwill. The Group adopted Accounting Standard Update (“ASU”) 2017-01, “Business Combination (Topic 805): Clarifying the Definition of a Business” for the transactions discussed in Note 4, as permitted by this guidance. In accordance with ASU 2017-01, a new screen test is introduced to evaluate whether a transaction should be accounted for as an acquisition and/or disposal of a business versus assets. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, then the set of transferred assets and activities is accounted for as an asset acquisition and the Company will allocate the cost of the acquisition including transaction costs to the assets acquired or liabilities assumed based on their related fair value. r) Asset Acquisition When the Group acquires other entities, if the assets acquired and liabilities assumed do not constitute a business, the transaction is accounted for as an asset acquisition. Assets are recognized based on the cost, which generally includes the transaction costs of the asset acquisition, and no gain or loss is recognized unless the fair value of noncash assets given as consideration differs from the assets’ carrying amounts on the Group’s books. If the consideration given is not in the form of cash (that is, in the form of noncash assets, liabilities incurred, or equity interest issued), measurement is based on either the cost to the acquiring entity or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. The cost of a group of assets acquired in an asset acquisition is allocated to the individual assets acquired or liabilities assumed based on their relative fair value and does not give risk to goodwill. s) Revenue recognition In accordance with ASC Topic 606, revenues are recognized when control of the promised goods or services is transferred to the Group’s customers, in an amount that reflects the consideration the Group expects to be entitled to in exchange for those goods or services. In determining when and how much revenue is recognized from contracts with customers, the Group performs the following five-step analysis: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; (5) recognize revenue when (or as) the entity satisfies a performance obligation. Wealth management service Revenue generated from providing wealth management service represents one-time distribution commissions, performance-based income and over-time income the Group earns by serving as a financial products distributor. It also included revenues generated from providing insurance brokerage service which represents one-time commission the Group earns by serving as a broker to insurance agency companies through facilitating the sales of various insurance products offered by the insurance companies. One-time distribution commissions One-time distribution commissions generated from the Group’s wealth management service are earned from (1) distribution of various financial products (mostly private-raised fund products) on behalf of the financial product issuers and (2) serving as a broker to insurance agency companies through facilitating the sales of various insurance products offered by the insurance companies. 1. Distribution of financial products For distribution of financial products, the Group enters into distribution agreements with the financial product issuers to specify key terms and conditions of each arrangement, which among other things, include a pre-agreed one-time distribution commission entitled by the Group in exchange for its distribution service. Such one-time distribution commissions entitled by the Group do not include rights of return, credits or discounts, rebates, price protection or other similar privileges, once earned. One-time distribution commissions are separately negotiated for each agreement, and calculated based on a pre-agreed annualized rate, the fixed lock-up period of the financial products (days), and total amounts purchased by the investors through the Group’s distribution channels. Revenues from one-time distribution commissions are recognized at a point in time upon establishment of a financial product, which is when the single performance obligation to provide distribution service of financial products on behalf of the product issuer to investors is fulfilled. The Group defines the “establishment of a financial product” for its revenue recognition purpose as the time when both of the following two criteria are met: (1) the investor referred by the Group has entered into a purchase or subscription contract with the product issuer and (2) the product issuer has issued a formal notice to confirm the establishment of a financial product. Different types of wealth management products would have the same timing on recognition of revenue but different commission rate. The one-time distribution commissions are earned and recognized when each individual investment is made, while the commission payments received from the product issuers are made in accordance with payment schedule agreed between the Group and the product issuer, which is usually less than three months after the end of the fund-raising period. 2. Insurance brokerage service The Group provides insurance brokerage service distributing insurance on behalf of the insurance agency companies and charges insurance agency companies for brokerage service commissions. The Group enters into insurance brokerage service contracts with insurance agency companies to specify key terms and conditions of each arrangement, which among other things, include a pre-agreed one-time commission entitled by the Group in exchange for its sales facilitation service provided to the insurance agency companies. These commissions are normally calculated as a percentage (which varies depending on the type of insurance products involved) of the premium to the insurance companies from sales facilitated by the Group in respect of an insurance product. 2.1 Initial placement of an insurance policy Insurance brokerage services are considered to be rendered and completed, and revenue is recognized, at the time an insurance policy becomes effective, that is, when the signed insurance policy is in place and the premium is collected by the insurance companies from the insured. The Group has satisfied the performance obligation to recognize revenue when the premiums are collected by the respective insurance companies and not before, because collectability is not ensured until receipt of the premium. Accordingly, the Group does not accrue any insurance brokerage service commission and fees prior to the receipt of the related premiums. For insurance products, there is generally a 10 to 15 days hesitation or clawback period after an initial placement of an insurance policy. During hesitation or clawback period, the insured has a legal right to unconditionally cancel the effective policy regardless of the reasons. The clawback provision entitled the insurance companies and brokers to recall any payment previously paid to the Group or to set off against any future payment. The revenues are reversed once clawback occurred. During the years ended June 30, 2021, 2022 and 2023, there were revenue amounted to RMB 0.17 million, RMB 0.25 million and RMB 0.61 million subject to clawback. The Group evaluates and updates its estimates of the clawback provision of each contract at each reporting date, based on historical experiences and various other assumptions that the Group believes to be reasonable under the circumstances and concludes that the occurrence of clawback from insurance companies and brokers are considered remote. The commission payment term from insurance agency companies is normally on a semi-month basis, with payment paid within 6-26 days after the amount of service fee of previous statement was confirmed by both parties. 2.2 Renewals of an insurance policy For the long-term insurance products, in addition to the initial commission earned, the Group is also entitled to subsequent renewal commission and compensation, and renewal performance bonus which represent variable considerations and are contingent on future renewals of initial policies or the Group achieves its performance target. Renewal commissions are determined by multiplying a pre-agreed charge rate with renewal premiums actually paid by the policyholders. Renewal compensation is determined by multiplying a pre-agreed charge rate with certain insurance products’ renewal premiums actually paid by the policyholders. Renewal performance bonus is variable according to different threshold of the total renewal premiums. When making estimates of the amount of variable consideration to which the Group expects to be entitled, the Group uses the expected value method and evaluates many factors, including but not limited to, insurance companies mix, product mix, renewal term of various products, renewal premium rates and commission rates, to determine the method(s) of measurement, relevant inputs and the underlying assumptions. The Group considers constraints as well when determining the amount which should be included in the transaction price. For fiscal years prior to 2023, revenue related to the variable consideration is recorded when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, i.e., when a policyholder pays the renewal premium to the insurance company, and the policy is renewed because the Group was not able to conclude a significant reversal to the estimated variable consideration is not probable, considering factors such as a) the Group has limited history of selling its current insurance products with its current customers, such that the Group’s past experience in outdated products is of little predictive value in renewal(s) rate estimate; b) the occurrence of a renewal is outside the Group’s control and the estimate of renewal premium rates is complex and requires significant assumptions; and c) the contingency lasts across a long period of time. The Group performs ongoing evaluation of the appropriateness of the constraint applied, and will consider the sufficiency of evidence that would suggest that the long-term expectation underlying the assumptions has changed. Starting from July 1, 2022 the Group believes that it has already accumulated adequate scale of historical data and experiences at a confidence level that through which the Group can utilize to make a reasonable estimate of variable considerations over its portfolio of contracts. The estimated renewal commissions are contingent on future renewals of initial policies or achievement of certain performance targets. Given the material uncertainty around the future renewal of the insurance policies, the estimated renewal commissions expected to be collected are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty is subsequently resolved. The judgment and assumptions are continuously re-evaluated and adjusted as needed along with the accumulation of historical experiences and data when new information becomes available. Actual renewal commissions in the future may differ significantly from those previously estimated. For the year ended June 30, 2021, 2022 and 2023, the Group recognized revenues related to estimated variable renewal commissions with respect to long-term insurance products amounting to nil, nil and RMB33,491, respectively. Performance-based income In some of the Group’s fund distribution arrangements, the Group is also entitled to a performance-based income, which is based on the extend by which the related fund’s investments performance exceeds a hurdle rate. Such performance-based fees are a form of variable consideration, and are typically calculated and distributed when the cumulative return of the fund can be determined. Such performance-based income is typically recognized as revenues at a point in time, usually when the fund liquidates and the cumulative return of the fund can be determined. The Group does not bear any loss from the investors’ investments nor provides any guarantees of return with respect to the products it distributes. Over-time income In some of the Group’s fund distribution arrangements, the Group is also entitled to client maintenance fees. After the investors purchased the products, the Group has the obligation to perform customer account management, information books keeping, contracts storage and other daily maintenance duties. After the contract is established, there are no significant judgments made when determining the transaction price. As the Group provides these services throughout the contract term, revenue is calculated on daily basis over the contract term. The agreements do not include rights of return, credits or discounts, rebates, price protection or other similar privileges. Payment of client maintenance fees are normally on a regular basis (typically quarterly) and are not subject to clawback once determined. Asset management service Revenues generated from providing asset management service represents management fees and performance-based income the Group earns by serving as a fund manager. Management fees Management fees generated from the Group’s asset management services are earned from providing investment management service throughout the duration of various investment funds, which represents a performance obligation that is satisfied over time. Revenues of management fees are recognized over time on a monthly basis over the contract term, which is calculated in accordance with the respective fund contract or mandate agreement, either as a percentage of the total investments made by the investors or as a percentage of the fair value of the fund’s or mandate’s net assets, calculated regularly. The management fees do not include any rights of return, credits or discounts, rebates, price protection or other similar

Acquisitions

Acquisitions	12 Months Ended
	Jun. 30, 2023
Acquisitions
Acquisitions	4. Acquisitions Acquisition of Grand Doctor Medical Co., Ltd. On January 27, 2022, for the purpose of entering into high-end health management business, through Hywin Health Management (Shanghai) Co., Ltd. (“Hywin Health Management”), a subsidiary of the Group’s VIE, the Group acquired 65.26% equity interest of Grand Doctor Medical Co., Ltd. from third parties for a cash consideration of RMB80,500. As of June 30, 2022, the acquisition consideration payable amounts to RMB15,300 which has been paid off in July 2022. The acquisition was accounted for as a business combination. Accordingly, the acquired assets and liabilities were recorded at their fair value at the date of acquisition. The purchase price allocation was based on a valuation analysis that utilized and considered generally accepted valuation methodologies such as the income and cost approach. The Group engaged a third-party valuation firm to assist with the valuation of assets acquired and liabilities assumed in this business combination. The determination and allocation of fair values to the identifiable assets acquired and liabilities assumed are based on various assumptions and valuation methodologies requiring considerable judgment from management. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determine discount rates to be used based on the risk inherent in the related activity’s current business model and industry comparisons. Terminal values are based on the expected life of assets, forecasted life cycle and forecasted cash flows over that period. The table below presented the allocation of purchase price to the major classes of assets and liabilities acquired as of January 27, 2022: ​ ​ ​ ​ ​ ​ Amount Allocated ​ ​ RMB US$ Identifiable assets acquired and liabilities assumed Cash and cash equivalents 3,736 557 Other current assets 21,897 3,263 Property and equipment and other non-current assets 23,486 3,499 Other current liabilities (19,413) (2,892) Acquired intangible assets: -- Internet Hospital License 3,600 536 -- Customer Relationship 2,600 387 Identifiable assets acquired and liabilities assumed (a) 35,906 5,350 Redeemable noncontrolling interest (b) 30,600 4,559 Consideration (c) 80,500 11,995 Goodwill (c+b-a) 75,194 11,204 ​ The net revenue and net loss of Grand Doctor since the acquisition date and that were included in the Company’s consolidated statements of income for the year ended June 30, 2022 are RMB422 and RMB9,406, respectively. The net revenue and net loss of Grand Doctor that were included in the Company’s consolidated statements of income for the year ended June 30, 2023 are RMB9,835 and RMB19,695, respectively. For the years ended June 30, 2021, 2022 and 2023, the Group recognized impairment of goodwill of nil, nil and RMB35,412 respectively for the reporting unit of Grand Doctor. The acquisition of Grand Doctor Medical Co., Ltd. demonstrates the Group’s continued commitment to high-end health management business. Goodwill arising from this acquisition was attributable to the synergies expected from the combined operations of Grand Doctor Medical Co., Ltd. and the Group, which can provide comprehensive and top-of-class one-stop healthcare solutions to the Group’s clients. The Group did not expect the goodwill recognized to be deductible for income tax purposes. Prior to the acquisition, Grand Doctor did not prepare its financial statements in accordance with US GAAP. The Group determined that the cost of reconstructing the financial statement of Grand Doctor for the periods prior to the acquisition outweighed the benefits. Based on an assessment of the financial performance and a comparison of Grand Doctor’s and the Group’s financial performance for the fiscal year prior to the acquisition, the Group did not consider Grand Doctor on its own to be material to the Group. Thus, the Group’s management believes that the presentation of pro forma financial information with respect to the results of operations of the Group for the business combination is impractical. Acquisition of Beijing iLife 3 Technology Co., Ltd. On August 25, 2022, the Company entered into a series of definitive share transfer agreements and capital increase agreement with Beijing iLife3 Technology Co. Ltd (“Life Infinity”), one of the leading integrated health management service providers in China, and its existing shareholders with an aggregate purchase consideration of approximately RMB141,232 in cash to acquire 63.39% equity interest in Life Infinity. The acquisition was accounted for as a business combination. Accordingly, the acquired assets and liabilities were recorded at their fair value at the date of acquisition. The purchase price allocation was based on a valuation analysis that utilized and considered generally accepted valuation methodologies such as the income and cost approach. The Group engaged a third-party valuation firm to assist with the valuation of assets acquired and liabilities assumed in this business combination. The determination and allocation of fair values to the identifiable assets acquired and liabilities assumed are based on various assumptions and valuation methodologies requiring considerable judgment from management. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determine discount rates to be used based on the risk inherent in the related activity’s current business model and industry comparisons. Terminal values are based on the expected life of assets, forecasted life cycle and forecasted cash flows over that period. The table below presented the allocation of purchase price to the major classes of assets and liabilities acquired as of August 25, 2022: ​ ​ ​ ​ ​ ​ ​ ​ Amount Allocated ​ RMB US$ ​ ​ ​ ​ ​ Identifiable assets acquired and liabilities assumed ​ ​ ​ ​ Cash and cash equivalents ​ 6,905 ​ 956 Other current assets ​ 106,596 ​ 14,752 Property and equipment and other non-current assets ​ 19,569 ​ 2,708 Other current liabilities ​ (138,262) ​ (19,134) Acquired intangible assets: ​ ​ ​ ​ -- Trademark ​ 41,283 ​ 5,713 -- Internet Hospital License ​ 3,169 ​ 439 -- Customer Relationship ​ 22,684 ​ 3,139 Acquired deferred tax liability: ​ (16,784) ​ (2,323) Identifiable assets acquired and liabilities assumed (a) ​ 45,160 ​ 6,250 Noncontrolling interests(b) ​ 88,292 ​ 12,219 Consideration (c) ​ 141,232 ​ 19,546 Goodwill (c+b-a) ​ 184,364 ​ 25,515 ​ The net revenue and net loss of Life Infinity since the acquisition date and that were included in the Company's consolidated statements of income for the year ended June 30, 2023 are RMB60,502 and RMB14,017, respectively. The acquisition of Beijing iLife 3 Technology Co., Ltd. demonstrates the Group’s continued commitment to high-end health management business. Goodwill arising from this acquisition was attributable to the synergies expected from the combined operations of Beijing iLife 3 Technology Co., Ltd. and the Group, which can provide comprehensive and top-of-class one-stop healthcare solutions to the Group’s clients. The Group did not expect the goodwill recognized to be deductible for income tax purposes. Prior to the acquisition, Life Infinity did not prepare its financial statements in accordance with US GAAP. The Group determined that the cost of reconstructing the financial statement of Life Infinity for the periods prior to the acquisition outweighed the benefits. Based on an assessment of the financial performance and a comparison of Life Infinity’s and the Group’s financial performance for the fiscal year prior to the acquisition, the Group did not consider Life Infinity on its own to be material to the Group. Thus, the Group’s management believes that the presentation of pro forma financial information with respect to the results of operations of the Group for the business combination is impractical. Acquisition of Sincerity and Compassion Health Management Center On September 1, 2022, the Company entered into an investment agreement with independent third parties, to obtain 65% equity interest of Sincerity and Compassion Health Management Center with a consideration of RMB 48,750 . The acquisition was accounted for as a business combination. Accordingly, the acquired assets and liabilities were recorded at their fair value at the date of acquisition. The purchase price allocation was based on a valuation analysis that utilized and considered generally accepted valuation methodologies such as the income and cost approach. The Group engaged a third-party valuation firm to assist with the valuation of assets acquired and liabilities assumed in this business combination. The determination and allocation of fair values to the identifiable assets acquired and liabilities assumed are based on various assumptions and valuation methodologies requiring considerable judgment from management. The most significant variables in these valuations are discount rates, terminal values, the number of years on which to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. The Group determine discount rates to be used based on the risk inherent in the related activity’s current business model and industry comparisons. Terminal values are based on the expected life of assets, forecasted life cycle and forecasted cash flows over that period. The table below presented the allocation of purchase price to the major classes of assets and liabilities acquired as of September 1, 2022: ​ ​ ​ ​ ​ ​ ​ ​ Amount Allocated ​ RMB US$ ​ ​ ​ ​ ​ Identifiable assets acquired and liabilities assumed ​ ​ ​ ​ Cash and cash equivalents ​ 73 ​ 10 Other current assets ​ 2,707 ​ 375 Property and equipment and other non-current assets ​ 34,007 ​ 4,706 Other current liabilities ​ (7,400) ​ (1,024) Acquired intangible assets: ​ ​ ​ ​ -- Trademark ​ 3,490 ​ 483 -- ​ 2,572 ​ 356 Acquired deferred tax liability: ​ (1,515) ​ (210) Identifiable assets acquired and liabilities assumed (a) ​ 33,934 ​ 4,696 Noncontrolling interests(b) ​ 18,750 ​ 2,595 Consideration (c) ​ 48,750 ​ 6,747 Goodwill (c+b-a) ​ 33,566 ​ 4,645 ​ The net revenue and net loss of SCHMC since the acquisition date and that were included in the Company’s consolidated statements of income for the year ended June 30, 2023 are RMB16,423 and RMB8,430, respectively. ​ The acquisition of Sincerity and Compassion Health Management Center demonstrates the Group’s continued commitment to high-end health management business. Goodwill arising from this acquisition was attributable to the synergies expected from the combined operations of Sincerity and Compassion Health Management Center and the Group, which can provide comprehensive and top-of-class one-stop healthcare solutions to the Group’s clients. The Group did not expect the goodwill recognized to be deductible for income tax purposes. Prior to the acquisition, SCHMC did not prepare its financial statements in accordance with US GAAP. The Group determined that the cost of reconstructing the financial statement of SCHMC for the periods prior to the acquisition outweighed the benefits. Based on an assessment of the financial performance and a comparison of SCHMC and the Group’s financial performance for the fiscal year prior to the acquisition, the Group did not consider SCHMC on its own to be material to the Group. Thus, the Group’s management believes that the presentation of pro forma financial information with respect to the results of operations of the Group for the business combination is impractical.

Deposits, Prepayments and Other

Deposits, Prepayments and Other Current Assets	12 Months Ended
	Jun. 30, 2023
Deposits, Prepayments and Other Current Assets
Deposits, Prepayments and Other Current Assets	5. Deposits, Prepayments and Other Current Assets ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Deposits for office spaces leases 24,852 25,819 3,573 Prepaid property management fee 16,975 ​ 2,540 ​ 352 Other current assets 9,377 ​ 18,033 ​ 2,495 ​ 51,204 ​ 46,392 ​ 6,420 6. ​

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Jun. 30, 2023
Property and Equipment, net
Property and Equipment, net	6. Property and Equipment, net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Real estate property (1) ​ 300,757 ​ 300,757 ​ 41,623 Leasehold improvements 133,163 177,436 24,556 Electronic equipment 66,590 113,425 15,697 Furniture, fixtures and other equipment 21,840 22,027 3,048 Motor vehicles 2,533 2,533 351 Property and equipment, cost 524,883 616,178 85,275 Less: accumulated depreciation (199,771) (266,493) (36,881) ​ 325,112 349,685 48,394 Depreciation expenses for the years ended June 30, 2021, 2022 and 2023 were approximately RMB18,715, RMB25,448 and RMB41,242, respectively. (1) On December 9, 2021, the Group entered into a Share Purchase Agreement to purchase 100% equity interest of Shanghai Yulan Real Property Co., Ltd., Shanghai Suxiao Real Property Co., Ltd., Shanghai Danxiao Real Property Co. Ltd., and Shanghai Biyu Real Property Co., Ltd. (collectively refer to as the “Real Property Companies”), who are the owners of 3rd and 4th floor of No. 8, Yincheng Middle Road (the “Property”), the Group’s current principal office. The current principal office was leased from the Real Property Companies before the acquisition. The consideration for acquiring the Real Property Companies is RMB36,338 cash as well as the assumption of liabilities of Real Property Companies of RMB273,950 to a third party. There is no noncash or contingent consideration. As of June 30, 2023, the Group has paid full amount of the cash consideration and RMB200,000 liabilities assumed in this acquisition to a third party. The acquisition is accounted as an asset acquisition since substantially all the fair value of the gross assets acquired is concentrated in a single group of identifiable assets. The excess of consideration over fair value of the assets acquired was allocated to property and equipment. For the years ended June 30, 2021, 2022 and 2023, no impairment loss was recognized for the Group’s property and equipment.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Jun. 30, 2023
Intangible Assets, Net
Intangible Assets, Net	7. Intangible Assets, Net ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Computer software 28,478 34,547 4,782 Licenses 15,648 16,673 2,307 Internet Hospital License ​ 3,600 ​ 6,769 ​ 937 Customer Relationship ​ 2,600 ​ 27,857 ​ 3,855 Trademark ​ — ​ 44,773 ​ 6,196 Intangible assets, cost 50,326 130,619 18,077 Less: accumulated amortization (16,778) (29,806) (4,125) accumulated impairment ​ — ​ (2,210) ​ (306) ​ 33,548 98,603 13,646 ​ Amortization expenses for the years ended June 30, 2021, 2022 and 2023 were approximately RMB6,879, RMB2,879 and RMB13,028, respectively. For the years ended June 30, 2021, 2022 and 2023, impairment loss of nil, nil and RMB2,210 was recognized for the Group’s intangible assets.

Goodwill

Goodwill	12 Months Ended
	Jun. 30, 2023
Goodwill.
Goodwill	8. Goodwill Changes in the carrying amount of goodwill for the years ended June 30, 2022 and 2023 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grand Life ​ ​ ​ ​ ​ Doctor ​ Infinity ​ SCHMC ​ Total ​ Total ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ US$ Balance as of June 30, 2021 — — — — — Additions 75,194 — — 75,194 11,204 Balance as of June 30, 2022 75,194 — — 75,194 11,204 Additions — 184,364 33,566 217,930 30,160 Impairment (35,412) — — (35,412) (5,100) Exchange translation adjustment — — — — (598) Balance as of June 30, 2023 39,782 184,364 33,566 257,712 35,666 ​ For the years ended June 30, 2021, 2022 and 2023, impairment loss of nil, nil and RMB35,412 was recognized for the Group’s goodwill.

Leases

Leases	12 Months Ended
	Jun. 30, 2023
Leases
Leases	9. Leases Operating leases as lessee The Group entered into operating lease agreements primarily for offices. As of June 30, 2023, the Group’s operating leases had a weighted average remaining lease term of 3.39 years. As of the same dates, the Company’s operating leases had a weighted average discount rate of 4.45%. The following tables shows operating lease right-of-use assets and lease liabilities, and the associated financial statement line items: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ Assets Operating lease right-of-use assets, net — 186,307 25,784 ​ ​ ​ ​ ​ ​ ​ Liabilities Operating lease liabilities, current — 83,573 11,566 Operating lease liabilities, non-current — 100,521 13,911 ​ The components of lease expenses are as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the year ended ​ June 30, 2023 ​ ​ RMB US$ Operating lease expense ​ ​ ​ ​ Amortization of right-of-use assets 76,696 11,047 Interest of lease liabilities 9,113 1,313 Short term lease expense 4,069 586 Total 89,878 12,946 ​ Supplemental cash flow information related to leases for the years ended June 30, 2021, 2022 and 2023 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ ​ RMB RMB RMB US$ Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases — — 77,887 11,218 ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental noncash information: — — Effect on operating assets upon the adoption of ASU 2016-13 on July 1, 2022 — — 204,296 29,425 ​ ​ ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease obligations, net of decrease of right-of-use assets for early terminations — — 48,572 6,996 ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer of prepayment of other liabilities to lease liabilities upon the adoption of ASU 2016-13 on July 1, 2022 — — 10,135 1,460 ​ Maturities of lease liabilities were as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2023 2023 ​ ​ RMB ​ US$ Twelve months ending June 30, 2024 98,941 13,693 2025 51,671 7,151 2026 24,003 3,322 2027 16,954 2,346 2028 10,770 1,490 Thereafter 3,953 547 Total lease payments 206,292 28,549 Less: imputed interest (22,198) (3,072) Total 184,094 25,477 10. ​

Consideration payable and other

Consideration payable and other payables	12 Months Ended
	Jun. 30, 2023
Consideration payable and other payables
Consideration payable and other payables	11. Consideration payable and other payables ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ ​ 2022 ​ 2023 ​ 2023 ​ RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ Value added tax and other taxes payable 225,598 245,381 ​ 33,959 Accrued payroll ​ 59,834 ​ 81,158 ​ 11,232 Service fee payables ​ 2,710 ​ 3,479 ​ 481 Payables related to property management fee ​ 12,102 ​ 1,287 ​ 178 Contingent liabilities related to legal proceedings ​ — ​ 1,034 ​ 143 Equity purchase payable (1) ​ 19,290 ​ 3,990 ​ 552 Payables related to the real property companies (2) ​ 73,950 ​ 73,950 ​ 10,234 Other current liabilities ​ 12,644 ​ 22,938 ​ 3,175 ​ ​ 406,128 ​ 433,217 ​ 59,954 (1) As of June 30, 2022, this amount represented the cash consideration payable to a third party for the acquisition of Grand Doctor (Note 4) of RMB 15,300 , which has been paid off in July 2022 as well as the cash consideration payable of RMB 3,990 to a third party for the acquisition of Shanghai Ziji in May 2020. As of June 30, 2022, this amount represented the cash consideration payable to a third party for the acquisition of Shanghai Ziji of RMB 3,990 in May 2020. (2) On December 9, 2021, Hywin Wealth Management Co., Ltd. acquires Shanghai Yulan Real Property Co., Ltd., Shanghai Suxiao Real Property Co., Ltd., Shanghai Danxiao Real Property Co. Ltd. and Shanghai Biyu Real Property Co., Ltd. (collectively refer to as the “Real Property Companies”). The Group took over the liabilities from the real property companies to a third party. The payables related to the real property companies amounted to RMB 73,950 , which is unsecured, interest free and payment on demand .

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2023
Income Taxes
Income Taxes	12. Income Taxes The entities within the Group file separate tax returns in the respective tax jurisdictions in which they operate. Cayman Islands The Company is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, the Company is not subject to income or capital gains taxes. In addition, dividend payments are not subject to withholdings tax in the Cayman Islands. British Virgin Islands (“BVI”) Under the current laws of the BVI, the Group’s subsidiaries incorporated in BVI are not subject to tax on income or capital gains. Additionally, upon payments of dividends by these BVI companies to its respective shareholders, no BVI withholding tax will be imposed. Hong Kong, PRC Under the current HK tax laws, before April 1, 2018, the income tax rate of Hong Kong was 16.5%. Effective from April 1, 2018, a two-tier corporate income tax system was officially implemented in Hong Kong, which is 8.25% for the first HK$2.0 million profits, and 16.5% for the subsequent profits. Under the HK tax laws, it is exempted from the Hong Kong income tax on its foreign-derived income. In addition, payments of dividends from Hong Kong subsidiaries to the Company are not subject to any Hong Kong withholding tax. Mainland, PRC The Group’s PRC subsidiaries and VIEs are governed by the income tax law of the PRC and are subject to the PRC enterprise income tax (“EIT”). The EIT rate of PRC is 25%, which applies to both domestic and foreign invested enterprises. For the years ended June 30, 2021, 2022 and 2023, the income tax rate of all the Group’s PRC subsidiaries and VIEs is 25%, except for Shanghai Ziji which enjoyed 12.5% preferential income tax rate since July 2022. For the years ended June 30, 2021, 2022 and 2023, the Group’s income/(loss) before tax consisted of: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ ​ RMB ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC 308,685 333,425 97,057 13,979 HK (12,929) (10,009) 95,720 13,787 Cayman and others (5) 1,031 (1,127) (162) ​ 295,751 324,447 191,650 27,604 ​ For the years ended June 30, 2021, 2022 and 2023, the Group’s income tax (expense)/ benefit consisted of: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current (86,367) (88,861) (73,221) (10,546) Deferred (1,727) 283 1,841 265 ​ (88,094) (88,578) (71,380) (10,281) ​ A reconciliation of the income tax expense determined at the PRC statutory income tax rate to the Group’s actual income tax expense is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income before income tax expense 295,751 324,447 191,650 27,604 ​ PRC statutory income tax rate 25 % 25 % 25 % 25 % Income tax at PRC statutory income tax rate (73,938) (81,112) (47,912) (6,901) ​ Impact of different tax rates in other jurisdictions (1,100) (969) 7,853 1,131 ​ Preferential tax treatments and tax holiday effects (73) 1,110 2,578 371 ​ Super deduction of qualified R&D expenditures 13 173 251 36 ​ Expenses not deductible (including expenses accrued for share-based compensation amounting to RMB5,487, RMB1,835 and RMB1,302 for the years ended June 30, 2021, 2022 and 2023, respectively) (9,737) (3,011) (5,662) (816) ​ Valuation allowance on deferred tax assets (3,259) (4,769) (19,635) (2,827) ​ Tax effect on Impairment loss of goodwill ​ — ​ — ​ (8,853) ​ (1,275) ​ Income tax expense (88,094) (88,578) (71,380) (10,281) ​ ​ The Group’s deferred tax liabilities were recorded as a result of recognition of the identifiable intangible assets acquired from various acquisition transactions. The Group’s deferred tax liabilities on June 30, 2023 and changes for the two years then ended were as follows: ​ ​ ​ ​ ​ Amount ​ RMB ​ ​ ​ Balance as of June 30, 2021 3,548 Decrease due to amortization of intangible assets (207) Increase due to acquisition ​ 651 Exchange translation adjustment 59 Balance as of June 30, 2022 ​ 4,051 Net deferred tax liabilities of June 30, 2022 ​ 3,400 Decrease due to amortization of intangible assets ​ (1,841) Increase due to acquisition ​ 18,300 Exchange translation adjustment ​ 169 Balance as of June 30, 2023 20,679 Net deferred tax liabilities as of June 30, 2023 ​ 20,028 Amount in US$ 2,772 ​ The Group’s deferred tax assets on June 30, 2022 and 2023 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ Tax loss carry forward 17,094 51,373 7,110 Net operating losses acquired through Acquisition ​ 16,259 ​ 50,821 ​ 7,033 Others 324 588 82 Less, valuation allowance (32,301) (101,406) (14,034) Balance as of June 30, 2023 1,376 1,376 191 Net deferred tax assets as of June 30, 2023 ​ 725 ​ 725 ​ 100 ​ The Group’s deferred tax assets valuation allowance on June 30, 2023 and changes for the two years then ended were as follows: ​ ​ ​ ​ ​ Amount ​ RMB ​ ​ ​ Balance as of June 30, 2021 12,271 Increase during the year ​ 4,769 Increase due to acquisition of entities ​ 15,206 Exchange translation adjustment ​ 55 Balance as of June 30, 2022 ​ 32,301 Increase during the year ​ 19,635 Increase due to acquisition of entities ​ 50,821 Decrease due to NOL expiration ​ (1,558) Exchange translation adjustment ​ 207 Balance as of June 30, 2023 ​ 101,406 Amount in US$ 14,034 ​ Total net operating losses (NOLs) carryforwards of the Group’s subsidiaries and VIEs in mainland China is RMB112,370 and RMB404,934 as of June 30, 2022 and 2023, respectively. The NOLs carryforwards of the Group’s subsidiaries and VIEs in mainland China as of June 30, 2023 will expire between the calendar years 2024 through 2028. The NOLs carryforwards of the Group’s subsidiaries and VIEs in Hong Kong are RMB30,965 and RMB2,325 as of June 30, 2022 and 2023, respectively. The NOLs of the Group’s subsidiaries and VIEs in Hong Kong can be carried forward indefinitely. The related deferred tax assets were calculated based on the respective net operating losses incurred by each of subsidiaries and VIEs and the respective corresponding enacted tax rate that will be in effect in the period in which the losses are expected to be utilized. The Group considers positive and negative evidence to determine whether some portion or all of the deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of recent losses, forecasts of future profitability, the duration of statutory carry forward periods, the Group’s experience with tax attributes expiring unused and tax planning alternatives. Valuation allowances have been established for deferred tax assets based on a more-likely-than-not threshold. The Group’s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carry forward periods provided for in the tax laws. For the year ended June 30, 2022, the Group recorded an additional valuation allowance in a net amount of RMB19,975. For the year ended June 30, 2023, the Group recorded an additional valuation allowance in a net amount of RMB70,456. The current EIT law also imposes a 10% withholding income tax for dividends distributed by a foreign invested enterprise to its immediate holding company outside China. A lower withholding tax rate will be applied if there is a tax treaty arrangement between mainland China and the jurisdiction of the foreign holding company.

Redeemable noncontrolling inter

Redeemable noncontrolling interest	12 Months Ended
	Jun. 30, 2023
Redeemable noncontrolling interest
Redeemable noncontrolling interest	12. Redeemable noncontrolling interest During the business acquisition of Grand Doctor (Note 4), in addition to the cash consideration, the Group also granted each minority shareholders of Grand Doctor incremental rights as follows: Redemption The minority shareholder of Grand Doctor has the right to require the Group to redeem its shares held in Grand Doctor in the event (“Redemption Event”) that: I. II. III. For any condition above is triggered, the minority shareholder has the right to request the Group to redeem its shares held in Grand Doctor with the price of RMB1.4 per share within 30 days of the events’ happening. The redeemable noncontrolling interests of Grand Doctor are classified as mezzanine equity as they may be redeemed at the option of the minority shareholders of Grand Doctor on or after an agreed-upon date outside the sole control of the Group. The redeemable noncontrolling interests were initially recorded at fair value. At each reporting date, the Group evaluates the probability of occurrence of any Redemption Event. If it is probable that a Redemption Event will occur and the noncontrolling interests will become redeemable, the Group recognizes changes in carrying value immediately as the Redemption Event occurs and adjusts the carrying value of the mezzanine equity to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable noncontrolling interests shall be affected by charges against retained earnings, or additional paid-in capital in the absence of retained earnings. Accordingly, if the noncontrolling interests are not currently redeemable and it is not probable that the noncontrolling interests will become redeemable, subsequent adjustment of the amount presented in temporary equity is unnecessary.

Equity

Equity	12 Months Ended
	Jun. 30, 2023
Equity
Equity	13. Equity Ordinary shares As of June 30, 2020, 50,000,000 ordinary shares were issued at par value, equivalent to share capital of US$5. On March 26, 2021, the Company completed its IPO of 3,000,000 ADSs at US$10.00 per ADS on NASDAQ. Each ADS represents two ordinary shares of the Company. As of June 30, 2021, 56,000,000 ordinary shares were issued at par value, equivalent to share capital of US$6, which number of shares was same as that outstanding as of the issuance date of the financial statements. Contribution from Noncontrolling Shareholders In September 2022, the Company entered into an investment agreement to purchase 65% equity interest of Sincerity and Compassion Health Management Center. According to the investment agreement, after 65% equity interest of Sincerity and Compassion Health Management Center is purchased by the Company from the minority shareholders, the Company and the minority shareholders should make additional capital investment of RMB6,500 and RMB3,500, respectively. The Company and the minority shareholders still own 65% and 35% equity interest of Sincerity and Compassion Health Management Center immediately before and after the subscription, with no change in the ownership percentage. As a result of the subscription, the Company recognized noncontrolling interest of RMB3,500 for the additional capital contribution made by the minority shareholders. Contribution from a Shareholder The RMB68 is the contribution from a minority shareholder of Compassion Health Management Center to temporarily support the daily operation of the Compassion Health Management Center in the process of the acquisition.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jun. 30, 2023
Earnings Per Share
Earnings Per Share	14. Earnings Per Share Basic and diluted earnings per share is calculated as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ ​ RMB RMB RMB US$ Numerator: ​ ​ ​ ​ ​ ​ ​ ​ Net income attributable to shareholders of Hywin Holdings Ltd. 207,657 235,869 129,881 18,707 Denominator: ​ ​ ​ ​ ​ ​ ​ ​ Denominator for basic earnings per share: Weighted average number of ordinary shares outstanding 51,528 56,000 56,000 56,000 Dilutive effect of outstanding share options 1,992 1,980 1,972 1,972 Denominator for diluted earnings per share 53,520 57,980 57,972 57,972 Basic earnings per share 4.03 4.21 2.32 0.33 Diluted earnings per share 3.88 4.07 2.24 0.32 Basic earnings per ADS 8.05 8.42 4.64 0.67 Diluted earnings per ADS 7.76 8.14 4.48 0.65 ​

Restricted Net Assets

Restricted Net Assets	12 Months Ended
	Jun. 30, 2023
Restricted Net Assets
Restricted Net Assets	15. Restricted Net Assets A significant portion of the Group’s operations are conducted through its PRC (excluding Hong Kong) subsidiary and VIEs, the Group’s ability to pay dividends is primarily dependent on receiving distributions of funds from its PRC subsidiary and VIEs. Relevant PRC statutory laws and regulations permit payments of dividends by its PRC subsidiary and VIEs only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations, and after it has met the PRC requirements for appropriation to statutory reserves. Paid in capital of the PRC subsidiary and VIEs included in the Group’s consolidated net assets are also non-distributable for dividend purposes. In accordance with the PRC regulations on Enterprises with Foreign Investment, a WFOE established in the PRC is required to provide certain statutory reserves, namely general reserve fund, the enterprise expansion fund and staff welfare and bonus fund which are appropriated from net profit as reported in the enterprise’s PRC statutory accounts. A WFOE is required to allocate at least 10% of its annual after-tax profit to the general reserve until such reserve has reached 50% of its registered capital based on the enterprise’s PRC statutory accounts. Appropriations to the enterprise expansion fund and staff welfare and bonus fund are at the discretion of the board of directors. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. Hywin WFOE is subject to the above mandated restrictions on distributable profits. Additionally, in accordance with the Company Law of the PRC, a domestic enterprise is required to provide a statutory common reserve of at least 10% of its annual after-tax profit until such reserve has reached 50% of its registered capital based on the enterprise’s PRC statutory accounts. A domestic enterprise is also required to provide for a discretionary surplus reserve, at the discretion of the board of directors. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. All of the Group’s PRC consolidated VIEs are subject to the above mandated restrictions on distributable profits. As a result of these PRC laws and regulations, the Group’s PRC subsidiary and VIEs are restricted in their ability to transfer a portion of their net assets to the Company. As of June 30, 2022 and 2023, net assets restricted in the aggregate, which include paid-in capital and statutory reserve funds of the Group’s PRC subsidiary and VIEs, that are included in the Company’s consolidated net assets were approximately RMB440,723 and RMB473,369, respectively. Financial information of Parent Company The Company was incorporated on July 19, 2019 and became parent company of the Group upon the completion of the Reorganization on September 29, 2019. The following disclosures presented the financial positions of the Parent Company as of June 30, 2022 and 2023, and results of operations and cash flows for the years ended June 30, 2021, 2022 and 2023, as if the current corporate structure has been in existence throughout the periods presented. The condensed financial statements of the Parent Company have been prepared using the same accounting policies as set out in the Group’s consolidated financial statements except that the Parent Company used the equity method to account for investments in its subsidiaries and VIEs. The Parent Company, its subsidiaries and VIEs were included in the consolidated financial statements whereby the inter-company balances and transactions were eliminated upon consolidation. For the purpose of the Parent Company’s condensed financial statements, its investments in subsidiaries and VIEs are reported using the equity method of accounting. The Company is a Cayman Islands company, therefore, is not subjected to income taxes for all years presented. The footnote disclosures contain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated financial statements of the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Balance Sheets (In thousands, except for share and per share data, or otherwise stated) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ (RMB) (RMB) (US$) ​ ​ ​ ​ ​ ​ ​ Assets Investments in subsidiaries and VIEs 968,313 1,111,691 153,850 Total Assets 968,313 1,111,691 153,850 Liabilities and Equity ​ ​ ​ ​ ​ ​ ​ Equity: Ordinary shares (US$0.0001 par value; authorized 500,000,000 shares; issued and outstanding 56,000,000 shares as of June 30, 2022 and 2023, respectively) 36 36 5 Additional paid-in capital 510,390 515,665 71,364 Accumulated gain 449,429 579,310 80,172 Accumulated other comprehensive income 8,458 16,680 2,309 Total equity 968,313 1,111,691 153,850 ​ ​ ​ ​ ​ ​ ​ Total Liabilities and Equity 968,313 1,111,691 153,850 ​ Statements of Operations (In thousands, except for share and per share data, or otherwise stated) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Share of income from subsidiaries and VIEs 207,657 235,869 129,881 18,707 Net income 207,657 235,869 129,881 18,707 ​ Statements of Cash Flows (In thousands, except for share and per share data, or otherwise stated) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ ​ RMB ​ RMB ​ RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ — ​ 791 ​ 93 ​ 13 Cash flows from operating activities — 791 93 13 Investment in subsidiaries ​ (180,677) ​ — ​ — ​ — Cash flows from investing activities (180,677) — — — Proceeds from issuance of ordinary shares from IPO ​ 180,677 ​ — ​ — ​ — Cash flows from financing activities 180,677 — — — Effect of exchange rate changes — — 64 — Net change in cash and cash equivalents — 791 157 13 Cash and cash equivalents at beginning of the year — — 791 118 Cash and cash equivalents at end of the year — 791 948 131 ​

Employee Defined Contribution P

Employee Defined Contribution Plan	12 Months Ended
	Jun. 30, 2023
Employee Defined Contribution Plan
Employee Defined Contribution Plan	16. Employee Defined Contribution Plan Full time employees of the Group’s subsidiaries and VIEs in mainland and Hong Kong, the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. The related labor regulations of mainland and Hong Kong, PRC require that the Group make contributions to the government for these benefits based on certain percentages of the employees’ salaries. The employee benefits were expensed as incurred. The Group has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits were approximately RMB47,362, RMB73,694 and RMB100,338 for the years ended June 30, 2021, 2022 and 2023, respectively.

Concentration of Risk

Concentration of Risk	12 Months Ended
	Jun. 30, 2023
Concentration of Risk
Concentration of Risk	17. Concentration of Risk Credit risk Financial instruments that potentially subject the Group to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, accounts receivable, short-term loan receivables, due from related parties and deposit to suppliers. As of June 30, 2023, all of the Groups’ cash and cash equivalents and restricted cash was held by major financial institutions located in Mainland and Hong Kong, China. The Group believes that these financial institutions located in Mainland and Hong Kong China are of high credit quality. For accounts receivable, short-term loan receivables, due from related parties and deposit to suppliers, the Group extends credit based on an evaluation of the customer’s or other parties’ financial condition, generally without requiring collateral or other security. In order to minimize the credit risk, the Group delegated a team responsible for credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. Further, the Group reviews the recoverable amount of each individual receivable at each balance sheet date to ensure that adequate allowances are made for doubtful accounts. In this regard, the Group considers that the Group’s credit risk for accounts receivable, short-term loan receivables, due from related parties and deposit to suppliers is significantly reduced. Concentration of customers The following tables summarized the information about the Group’s concentration of customers for the years ended June 30, 2021, 2022 and 2023 or as of June 30, 2022 and 2023, respectively: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ A B C D E F G H ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 Revenues, customer concentration risk * ​ * ​ — ​ 18 % 22 % * ​ 16 % * ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, customer concentration risk * ​ * ​ 13 % 14 % 10 % * ​ * * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, customer concentration risk 18 % 11 % * * — ​ — ​ * ​ * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 (1) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable (from third parties and related parties), customer concentration risk * * — * * * * 15 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 (1) ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable (from third parties and related parties), customer concentration risk * * * ​ 13 % 36 % 12 % * * ​ (1) The denominator for the calculation of accounts receivable, customer concentration risk was the total amount of accounts receivable from third parties, contract assets from third parties and accounts receivable from related parties as of June 30, 2022 and 2023, respectively. * Less than 10%. - No transaction incurred for the reporting period/no balance existed as of the reporting date.

Related Party Balances and Tran

Related Party Balances and Transactions	12 Months Ended
	Jun. 30, 2023
Related Party Balances and Transactions
Related Party Balances and Transactions	18. Related Party Balances and Transactions The following is a list of the related parties with whom the Group conducted significant transactions during the three years ended June 30, 2023, and their relationship with the Group: ​ Name of the related parties Relation with the Group ​ ​ ​ Hywin Financial Holding Group Co., Ltd. (“Hywin Financial Holding”) An entity ultimately controlled by Mr. HAN Hongwei Ms. WANG Dian Senior executive officer Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I ​ Non-controlling interest shareholder of Grand Doctor ​ ​ Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II ​ Non-controlling interest shareholder of Grand Doctor ​ ​ Hywin Asset Management Co., Ltd. a direct subsidiary of Hywin Financial Holding Beijing Boyi Kangsheng Investment Consulting Co., Ltd Non-controlling interest shareholder of Life Infinity ​ As of June 30, 2022 and 2023, the related party balances of the Group are listed as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ Amount due from related parties ​ ​ ​ ​ ​ ​ Amounts lent to a related party (1) : ​ ​ ​ ​ ​ Hywin Financial Holding Group Co., Ltd. (“Hywin Financial Holding”) 66,103 — — ​ ​ ​ ​ Due from related parties total 66,103 — — ​ ​ ​ ​ ​ ​ ​ ​ Amount due to related parties ​ ​ ​ ​ ​ ​ ​ Loans borrowed from and interest payable to related parties, net Wang Dian 1,891 1,891 262 Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I (4) 5,005 5,401 747 Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II (4) 6,370 6,874 951 Beijing Boyi Kangsheng Investment Consulting Co., Ltd ​ — ​ 1,000 ​ 138 Others ​ 406 ​ 407 ​ 57 ​ ​ 13,672 ​ 15,573 ​ 2,155 ​ ​ ​ ​ ​ ​ ​ Dividend payable to a related party: ​ ​ ​ ​ ​ Ms. Wang Dian 22,500 ​ 22,500 ​ 3,114 ​ ​ ​ ​ ​ ​ ​ Due to related parties-total 36,172 ​ 38,073 ​ 5,269 ​ For the years ended June 30, 2021, 2022 and 2023, the significant related party transactions summarized by different natures are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended June 30, ​ 2021 2022 2023 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Wealth management services revenues from a related party Hywin Asset Management Co., Ltd. 3,144 4,499 1,679 241 ​ 3,144 4,499 1,679 241 Net loans borrowed from/lent to related parties (2) Loan lent to a related party, net ​ ​ ​ ​ ​ ​ ​ Hywin Financial Holding Group Co., Ltd. ​ 1,579 — — — ​ 1,579 — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collection of loans lent to related parties, net Hywin Financial Holding Group Co., Ltd. — 60,000 66,103 9,521 ​ — 60,000 66,103 9,521 ​ ​ ​ ​ ​ ​ ​ ​ ​ Loans borrowed from related parties, net ​ ​ ​ ​ Others 321 — — — ​ ​ 321 — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loans and interest payables took over from acquiring Grand Doctor Medical Co., Ltd. (3) ​ ​ ​ ​ ​ ​ ​ ​ Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I — 4,840 — — Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II — 6,160 — — ​ — 11,000 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expenses charged by related parties Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I — 165 396 57 Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II — 210 504 73 ​ — 375 900 130 ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loans took over from acquiring Beijing iLife 3 Technology Co., Ltd. (4) Beijing Boyi Kangsheng Investment Consulting Co., Ltd — — 1,000 144 ​ — — 1,000 144 Note 1 The loan was lent to related party for the purpose of supporting the business development of the related party, which was unsecured, interest free and payment on demand. ​ Note 2 The loans lent to/borrowed from the related party are unsecured, interest free and payment on demand. Note 3 On January 27, 2022, the Group entered into a series of definitive share transfer agreements and capital increase agreement to purchase 65.26% equity interest of Grand Doctor Medical Co., Ltd., which has net loans amounted to RMB10,000 payable to, minority shareholder of Grand Doctor Medical Co., Ltd., Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I and Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II. The loans borrowed from Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I and Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II are unsecured, payment on demand and 9% interest rate. Note 4 On August 25, 2022, the Company entered into a series of definitive share transfer agreements and capital increase agreement with Beijing iLife3 Technology Co. Ltd and its existing shareholders with an aggregate purchase consideration of approximately RMB141,232 in cash to acquire 63.39% equity interest in Life Infinity., which has net loans amounted to RMB1,000 payable to, minority shareholder of Beijing iLife3 Technology Co. Ltd, Beijing Boyi Kangsheng Investment Consulting Co., Ltd. The loans borrowed from Beijing Boyi Kangsheng Investment Consulting Co., Ltd are unsecured, interest free and payment on demand.

Share-based Compensation

Share-based Compensation	12 Months Ended
	Jun. 30, 2023
Share-based Compensation
Share-based Compensation	19. Share-based Compensation On January 1, 2016, January 1, 2017 and January 8, 2018, one of the Group’s consolidated VIEs, Hywin Wealth Management granted and issued options to its employees for the purchase of an aggregate of 8,998,465 shares of Hywin Wealth Management. The option exercise price was set at RMB1.23, RMB1.35 and RMB1.83 per share for the options granted on January 1, 2016, 2017 and January 8, 2018, respectively. All these options were vested upon issuance. The options issued had a repurchase feature, which gave the awardees the right to require the Group to repurchase part or all of the options for the employees hold for cash. Given the condition of the grants, vests, repurchases and exercises of the relevant options issued historically were all under similar conditions, the Group considered all these options were granted and issued under a share incentive plan, or the 2018 Option Plan. On September 30, 2019, the Company adopted a share option plan (the “2019 Option Plan”) for the employees to purchase ordinary shares of the Company. Under the 2019 Option Plan, the maximum aggregate number of ordinary shares available for issuance would be 2,250,000 ordinary shares. Each grantee of the 2018 Option Plan entered into an amended grant letter with Hywin Wealth Management and the Company, all parties agreed to replace the issued and outstanding options granted by Hywin Wealth Management with the options granted by the Company under the 2019 Option Plan, and terminate the 2018 Option Plan, with each one option granted by the Company replacing ten options granted by Hywin Wealth Management. The exercise price replaced by the 2019 Option Plan was US$1.894, US$1.946 and US$2.801 per share for the options originally granted on January 1, 2016, 2017 and January 8, 2018, respectively. The 2019 Option Plan also granted to the employees 1,499,753 new options of the Company with nil exercise price. The exercise period of any options granted under the 2019 Option Plan shall start from one year after the IPO of the Company through December 31, 2023. The options granted and issued under the 2018 Option Plan were treated as liabilities due to the repurchase feature attached, allowing the employees to cause the Company to repurchase part or all of the options they hold, which permitted the employees to avoid bearing the risks and rewards normally associated with equity share ownership. As a result, they were measured at fair value when granted and remeasured as of each reporting date, with the changes in fair value of these liability classified awards be recorded in earnings in each reporting period. As of September 30, 2019, the options granted and issued under the 2018 Option plan were replaced by the 2019 Option plan with no repurchase feature. According to ASC718, the transaction was classified as modification from a liability award to an equity award. The aggregate amount of compensation cost recognized is generally the fair-value-based measure of the award on the modification date, and no longer has to be remeasured at a fair-value-based amount in each reporting period until settlement. The options under 2019 Option plan granted to employees contain an explicit service condition, which the options will be considered to be forfeited if the grantees resigned within 5 years after the date they joined the 2018 Option plan or 2019 Option plan (“5-year condition”). Also, all grantees were restricted to convert the options into ordinary shares until a certain period subsequent to the IPO date (“lock up period”). If the grantee resigned from the Company before the IPO or during the lock up period, the Company has the right to cancel their options. The 5-year condition and lock up period are service condition and the exercise of the options were contingent to the IPO, which is a performance condition. Under ASC 718, if the vesting (or exercisability) of an award is based on the satisfaction of both a service and performance condition, the entity must initially determine which outcomes are probable and recognize the compensation cost over the longer of the explicit or implicit service period. Because an IPO generally is not considered to be probable until the IPO is effective, the compensation cost of the 2019 Option plan will only be recognized upon the completion of IPO based on the fair value of grant date as the cumulative effect on current and prior periods of the change in the estimated number of awards for which the requisite service is expected to be rendered. As of June 30, 2020, however, the Company considered the obligation under the 2018 Option plan still exist after the replacement of 2019 Option plan because no forfeiture is expected due to the replacement. As a result, previously recorded share-based compensation liabilities as of September 30, 2019 (i.e. RMB 6,560) based on fair value under 2018 Option plan would be transferred to equity, and the change in value due to the replacement would be recognized after the IPO occurs. As of March 26, 2021, the Company completed its IPO on NASDAQ, which is regarded as the milestone that it fulfilled both the performance and service condition. As such, the fair value of the options and the compensation cost under the 2019 Option plan should be recognized from March 26, 2021. The grant date of the 2019 Option plan is considered to be September 30, 2019. The requisite service period should start from the earliest signing date of the respective option plan until the later of the one year after IPO successfully and 5 years after earliest option plan signing date. No new options were granted since October 1, 2019. 781,270 and 946,897 options were exercisable as of June 30, 2022 and 2023. The following table summarizes the option activities under the 2018 Option Plan and 2019 Option Plan during the years ended June 30, 2021,2022 and 2023, respectively: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ ​ Remaining ​ Average ​ ​ ​ ​ Contractual ​ Exercise ​ Number of options Life (Years) Price (RMB) ​ ​ ​ ​ ​ ​ ​ Outstanding and exercisable, June 30, 2020 — — — Recognition of options originally under 2018 Option Plan and replaced by 2019 Option plan as of March 26, 2021 750,247 1.11 16.43 Recognition of new options granted under 2019 Option plan as of March 26, 2021 1,499,753 2.00 — Forfeited (235,613) — 0.74 Exercised ​ — ​ — ​ — Outstanding, June 30, 2021 2,014,387 1.48 5.29 Forfeited (102,084) — 1.21 Exercised — — — Outstanding, June 30, 2022 1,912,303 0.62 5.02 Forfeited ​ (28,500) ​ — ​ 1.27 Exercised ​ — ​ — ​ — Outstanding, June 30, 2023 ​ 1,883,803 ​ 0.15 ​ 5.03 ​ For the year ended June 30, 2021, 2,250,000 options were granted under the 2019 Option plan. The Company recognized share compensation expense for the share options under the 2019 Option plan of RMB21,947, RMB7,340 and RMB5,207 for the years ended June 30, 2021 2022 and 2023, respectively. As of June 30, 2023, there was approximately RMB725 of total unrecognized compensation cost related to unvested share options and the unrecognized compensation costs are expected to be recognized over a weighted average period of approximately 0.15 years.

Segment information

Segment information	12 Months Ended
	Jun. 30, 2023
Segment information
Segment information	20. Segment information The Company presents segment information after elimination of inter-company transactions. The following tables present the summary of each segment’s revenue, income from operations and net income which is considered as a segment operating performance measure, for the years ended June 30, 2021, 2022 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, 2023 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Total net revenues ​ 2,005,293 ​ 87,841 ​ (1,377) ​ 2,091,757 ​ 301,280 Income from operations 308,530 (111,145) — 197,385 28,430 Net income/(loss) 231,419 (111,149) — 120,270 17,323 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, 2022 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Total net revenues 1,941,691 422 — 1,942,113 300,786 Income from operations 337,775 (11,085) — 326,690 50,596 Net income/(loss) 247,359 (11,490) — 235,869 36,530 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, 2021 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Total net revenues 1,834,422 — — 1,834,422 277,107 Income from operations 281,606 — — 281,606 42,539 Net income/(loss) 207,657 — — 207,657 31,369 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Goodwill — 257,712 — 257,712 35,666 Other assets 2,154,194 296,324 (334,738) 2,115,780 292,809 Total assets 2,154,194 554,036 (334,738) 2,373,492 328,475 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Goodwill — 75,194 — 75,194 11,204 Other assets 1,665,803 42,415 — 1,708,218 254,525 Total assets 1,665,803 117,609 — 1,783,412 265,729 ​

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2023
Subsequent Events
Subsequent Events	21. Subsequent Events In September 2023, the Company won a bid to acquire the land use rights of a parcel of land with a total site area of 56,449.39 square meters and the above-ground construction in progress (collectively referred to as the “Real Property”), situated at 09-No.5-3, Boao Lecheng International Medical and Tourism Pilot Zone (“Boao Lecheng”), Hainan Province, the People’s Republic of China (the “PRC”) at a consideration of approximately RMB129,200. Hywin has already paid the consideration. The Real Property will be used to build Hywin’s first integrated health management center pilot project. The Group has evaluated subsequent events through the date of issuance of the consolidated financial statements, and did not identify any other subsequent events with material financial impact on the Group’s consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies
Basis of presentation	a) Basis of presentation The Group’s consolidated financial statements are prepared and presented in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Principles of consolidation and non-controlling interest	b) Principles of consolidation and non-controlling interest The Group’s consolidated financial statements include the accounts of the Company, its subsidiaries and its consolidated VIEs, of which the Company is the primary beneficiary, from the dates they were acquired or incorporated. All inter-company transactions and balances have been eliminated upon consolidation.
Use of estimates	c) Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of these consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Group continually evaluates these estimates and assumptions based on the most recently available information, historical experience and various other assumptions that the Group believes to be reasonable under the circumstances. Significant accounting estimates reflected in the Group’s consolidated financial statements include but are not limited to estimates and judgments applied in determination of allowance for doubtful receivables and loans, impairment losses for long-lived assets, impairment of goodwill and indefinite-lived intangibles, valuation allowance for deferred tax assets, the purchase price allocation in acquisitions and the renewal compensation for insurance. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from those estimates.
Foreign currency translation and transactions	d) Foreign currency translation and transactions The Group’s reporting currency is Renminbi (“RMB”). The Group’s operations are principally conducted through its subsidiaries and VIEs located in the PRC where RMB is the functional currency. For those subsidiaries and VIEs which are not located in mainland PRC and have the functional currency other than RMB, the financial statements are translated from their respective functional currencies into RMB. Assets and liabilities are translated using the exchange rate at each balance sheet date. Revenue and expenses are translated using average rates prevailing during each reporting period, and shareholders’ equity is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income/(loss) in shareholders’ equity. Translations of amounts from RMB into US$ are solely for the convenience of the reader and were calculated at the rate of US$1.00 = RMB 7.2258 on June 30, 2023 for balance sheet items, except equity, and US$1.00 = RMB 6.9429 for items in the statement of operation and comprehensive income, and statement of cash flow, representing the certificated exchange rate published by the People’s Bank of China. No representation is intended to imply that the RMB amounts could have been, or could be, converted, realized or settled into US$ at that rate on June 30, 2023, or at any other rate.
Cash and cash equivalents	e) Cash and cash equivalents Cash and cash equivalents consist of bank deposits, which are unrestricted as to withdrawal and use. The Group considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
Restricted cash	f) Restricted cash Restricted cash mainly represents the investors’ uninvested cash balances temporarily deposited in the Group’s bank accounts. These cash balances were under the custody and supervision of the designated financial institution as required by the China Securities Regulatory Commission (“CSRC”), for the purpose of preventing misuse of investors’ funds.
Term deposit	g) Term deposit Term deposit represent demand deposits placed with banks with original maturities of more than three months but less than one year. Interest earned is recorded as interest income in the consolidated statements of comprehensive income during the periods.
Accounts receivable, net	h) Accounts receivable, net The Group records accounts receivable at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Group’s best estimate of the amount of probable credit losses in the Group’s existing accounts receivable. The Group determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The aging schedule of the accounts receivable is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Less than 3 months 450,326 ​ 404,295 ​ 55,952 More than 3 months and less than 1 year 111,049 ​ 7,468 ​ 1,033 More than 1 year 2,999 ​ 3,371 ​ 467 Total 564,374 ​ 415,134 ​ 57,452 ​ The roll forward schedule of accounts receivable is as follows: ​ ​ ​ ​ ​ ​ ​ ​ Amount ​ RMB US$ Balance as of June 30, 2021 594,061 ​ 91,958 Revenue (including VAT) 2,055,534 ​ 318,352 Collections (2,085,221) ​ (326,218) Balance as of June 30, 2022 564,374 ​ 84,092 Acquisition of Life Infinity & SCHMC ​ 7,715 ​ 1,125 Revenue (including VAT) 2,197,657 ​ 316,533 Collections (2,354,648) ​ (344,298) Balance as of June 30, 2023 415,134 ​ 57,452 ​ As of June 30, 2022 and 2023, the Group recorded nil and nil allowances for doubtful accounts against its accounts receivable, respectively.
Property and equipment, net	i) Property and equipment, net The Group’s property and equipment are recorded at cost less accumulated depreciation and impairment loss, if any. Depreciation is calculated on the straight-line method after taking into account their respective estimated residual values over the following estimated useful lives: ​ ​ ​ ​ Real estate property 14 years Leasehold improvements Shorter of the remaining lease terms and estimated useful lives Electronic equipment 3- 16 Furniture, fixture and other equipment ​ 3- 14 Motor Vehicles 5 years ​ When property and equipment are retired or otherwise disposed of, resulting gain or loss is included in net income in the period of disposition. For the years ended June 30, 2021, 2022 and 2023, the Group recognized a loss of RMB81, RMB22 and RMB83 (US$12) from disposal of furniture, fixture and equipment, respectively, which were included in the Group’s other expenses.
Intangible assets, net	j) Intangible assets, net The Group’s intangible assets primarily consisted of software purchased from third-party suppliers, trademark, internet hospital license, customer relationship, Private Investment Fund Manager Certificate in PRC (“PRC private investment fund manager certificate”), Hong Kong Securities and Futures Commission financial licenses (“HKSFC financial licenses”), Membership of Hong Kong Professional Insurance Brokerage Association (“HK insurance brokerage license”) and others obtained through various business combination transactions. Estimated useful lives of intangible assets are as following: ​ ​ ​ ​ Software 3 Trademark 7 10 Customer relationship 10 years License indefinite life ​ Software is initially recorded at historic acquisition cost and amortized on a straight-line basis over the estimated useful lives of 3 to 5 years Trademark, internet hospital license and customer relationship acquired through the acquisition of Grand Doctor Medical Co., Ltd., Beijing iLife 3 Technology Co., Ltd. and Sincerity and Compassion Health Management Center were estimated by management based on the fair value of assets acquired. Amortization of trademark is recorded on the straight-line method based on the estimated useful lives which is 7-10 years. Internet hospital license is determined to have an indefinite life and it should not be amortized until its useful life is determined to be no longer indefinite. Amortization of customer relationship is recorded on the straight-line method based on the estimated useful lives which is 10 years. PRC private investment fund manager certificate, HKSFC financial licenses and HK insurance brokerage license acquired through the acquisition of Shenzhen Panying, Hywin Asset Management (Hong Kong) Limited and Hywin International Insurance Broker Limited, respectively, were initially recorded at cost, as the assets acquired and liabilities assumed in the respective transactions did not constitute a business, and the transactions were accounted for as asset acquisitions. PRC private investment fund manager certificate, HKSFC financial licenses and HK insurance brokerage license were determined to have an indefinite useful life. As a result, these intangible assets should not be amortized until its useful life is determined to be no longer indefinite. If an intangible asset that is not being amortized is subsequently determined to have a finite useful life, the asset will be tested for impairment and then be amortized prospectively over its estimated remaining useful life and accounted for in the same way as intangible assets subject to amortization.
Impairment of long-lived assets	k) Impairment of long-lived assets All long-lived assets, which include tangible long-lived assets and intangible long-lived assets with finite lives, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of the asset to the estimated undiscounted future cash flows expected to be generated by the assets. If the carrying amount of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount of the asset and its fair value. For the years ended June 30, 2021, 2022 and 2023, the Group recognized impairment of long-lived assets of nil, nil and RMB2,210 respectively. There were four reporting units of the Group: (1) the wealth unit, (2) Grand Doctor Medical Co., Ltd. (Grand Doctor) acquired on January 27, 2022, (3) Beijing iLife 3 Technology Co., Ltd. (Life Infinity) acquired on August 25, 2022, (4) Sincerity and Compassion Health Management Center (“SCHMC”) acquired on September 1, 2022. Impairment recorded for the year ended June 30, 2023 represented the amount by which the carrying value of the reporting unit of Grand Doctor exceeds their fair value, based on an annual impairment assessment. There were no impairments in other reporting units.
Goodwill	l) Goodwill Goodwill represents the excess of the purchase consideration over the acquisition date amounts of the identifiable tangible and intangible assets acquired and liabilities assumed from the acquired entity as a result of the Company’s acquisitions of interests in its subsidiaries. Goodwill is not amortized but is tested for impairment on an annual basis at each balance sheet date on June 30, or more frequently if events or changes in circumstances indicate that it might be impaired.
Impairment of goodwill and indefinite-lived intangible assets	m) Impairment of goodwill and indefinite-lived intangible assets In accordance with ASC 350, the Company may first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill impairment test. In the qualitative assessment, the Company considers factors such as macroeconomic conditions, industry and market considerations, overall financial performance of the reporting unit, and other specific information related to the operations, business plans and strategies of the reporting unit, including consideration of the impact of the COVID-19 pandemic. Based on the qualitative assessment, if it is more likely than not that the fair value of a reporting unit is less than the carrying amount, the quantitative impairment test is performed. The Company may also bypass the qualitative assessment and proceed directly to perform the quantitative impairment test. The Company adopted ASU 2017-04, from July 1, 2021, “Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”. After adopting this guidance, the Company performs the quantitative impairment test by comparing the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. If the carrying amount of a reporting unit exceeds its fair value, the amount by which the carrying amount exceeds the reporting unit’s fair value is recognized as impairment. Application of a goodwill impairment test requires significant management judgment, including the identification of reporting units, allocation of assets, liabilities and goodwill to reporting units, and determination of the fair value of each reporting unit. For the years ended June 30, 2021, 2022 and 2023, the Group recognized impairment of goodwill of nil, nil and RMB35,412 respectively. Impairment recorded in 2023 represents the amount by which the carrying value of the reporting unit of Grand Doctor exceeds their fair value, based on an annual goodwill impairment assessment. There were no impairments in other reporting units. An intangible asset that is not subject to amortization shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. Based on the qualitative assessment, if it is more likely than not that the fair value of an indefinite-lived intangible asset is less than the carrying value, a quantitative test to measure the amount of impairment must be performed. The quantitative impairment test compares the fair value of the asset with the carrying amount. If the carrying amount exceeds the fair value, then an impairment loss equal to that excess is recorded. For the years ended June 30, 2021, 2022 and 2023, there were no impairment recognized on indefinite-lived intangible assets.
Leases	n) Leases The Company determines if an arrangement is a lease at inception. Leases that transfer substantially all of the benefits and risks incidental to the ownership of assets are accounted for as finance leases as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases. The Company has no significant finance leases. The Company adopted Accounting Standard Update (“ASU”) 2016-02, “Leases (Topic 842)” from July 1, 2022. The Company recognizes lease liabilities and corresponding right-of-use assets on the balance sheet for leases. Operating lease right-of-use assets and operating lease liabilities are initially recognized based on the present value of future lease payments at lease commencement. The operating lease right-of-use asset also includes any lease payments made prior to lease commencement and the initial direct costs incurred by the lessee and is recorded net of any lease incentives received. As the interest rates implicit in most of the leases are not readily determinable, the Company uses the incremental borrowing rates based on the information available at lease commencement to determine the present value of the future lease payments. Operating lease expenses are recognized on a straight-line basis over the term of the lease. The Company elected not to recognize short-term leases with an initial lease term of twelve months or less.
Fair value of financial instruments	o) Fair value of financial instruments The Group’s financial instruments primarily consist of cash and cash equivalents, restricted cash, term deposit, accounts receivable, short-term loan receivables and due from related parties. The carrying values of these financial instrument approximate fair values due to their short maturities. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy which requires classification based on observable and unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Group evaluates its hierarchy disclosures each quarter.
Investors' Deposit	p) Investors’ Deposit The balance represents the investors’ uninvested cash balances temporarily deposited in the Groups bank account. These deposits were under the custody and supervision of the designated financial institution as required by CSRC, for the purpose of preventing misuse of investors’ funds.
Business combination	q) Business combination Business combinations are recorded using the acquisition method of accounting and, accordingly, the acquired assets and liabilities are recorded at their fair value at the date of acquisition. Any excess of acquisition consideration over the fair value of the acquired assets and liabilities, including identifiable intangible assets, is recorded as goodwill. The Group adopted Accounting Standard Update (“ASU”) 2017-01, “Business Combination (Topic 805): Clarifying the Definition of a Business” for the transactions discussed in Note 4, as permitted by this guidance. In accordance with ASU 2017-01, a new screen test is introduced to evaluate whether a transaction should be accounted for as an acquisition and/or disposal of a business versus assets. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, then the set of transferred assets and activities is accounted for as an asset acquisition and the Company will allocate the cost of the acquisition including transaction costs to the assets acquired or liabilities assumed based on their related fair value.
Asset Acquisition	r) Asset Acquisition When the Group acquires other entities, if the assets acquired and liabilities assumed do not constitute a business, the transaction is accounted for as an asset acquisition. Assets are recognized based on the cost, which generally includes the transaction costs of the asset acquisition, and no gain or loss is recognized unless the fair value of noncash assets given as consideration differs from the assets’ carrying amounts on the Group’s books. If the consideration given is not in the form of cash (that is, in the form of noncash assets, liabilities incurred, or equity interest issued), measurement is based on either the cost to the acquiring entity or the fair value of the assets (or net assets) acquired, whichever is more clearly evident and, thus, more reliably measurable. The cost of a group of assets acquired in an asset acquisition is allocated to the individual assets acquired or liabilities assumed based on their relative fair value and does not give risk to goodwill.
Revenue recognition	s) Revenue recognition In accordance with ASC Topic 606, revenues are recognized when control of the promised goods or services is transferred to the Group’s customers, in an amount that reflects the consideration the Group expects to be entitled to in exchange for those goods or services. In determining when and how much revenue is recognized from contracts with customers, the Group performs the following five-step analysis: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; (5) recognize revenue when (or as) the entity satisfies a performance obligation. Wealth management service Revenue generated from providing wealth management service represents one-time distribution commissions, performance-based income and over-time income the Group earns by serving as a financial products distributor. It also included revenues generated from providing insurance brokerage service which represents one-time commission the Group earns by serving as a broker to insurance agency companies through facilitating the sales of various insurance products offered by the insurance companies. One-time distribution commissions One-time distribution commissions generated from the Group’s wealth management service are earned from (1) distribution of various financial products (mostly private-raised fund products) on behalf of the financial product issuers and (2) serving as a broker to insurance agency companies through facilitating the sales of various insurance products offered by the insurance companies. 1. Distribution of financial products For distribution of financial products, the Group enters into distribution agreements with the financial product issuers to specify key terms and conditions of each arrangement, which among other things, include a pre-agreed one-time distribution commission entitled by the Group in exchange for its distribution service. Such one-time distribution commissions entitled by the Group do not include rights of return, credits or discounts, rebates, price protection or other similar privileges, once earned. One-time distribution commissions are separately negotiated for each agreement, and calculated based on a pre-agreed annualized rate, the fixed lock-up period of the financial products (days), and total amounts purchased by the investors through the Group’s distribution channels. Revenues from one-time distribution commissions are recognized at a point in time upon establishment of a financial product, which is when the single performance obligation to provide distribution service of financial products on behalf of the product issuer to investors is fulfilled. The Group defines the “establishment of a financial product” for its revenue recognition purpose as the time when both of the following two criteria are met: (1) the investor referred by the Group has entered into a purchase or subscription contract with the product issuer and (2) the product issuer has issued a formal notice to confirm the establishment of a financial product. Different types of wealth management products would have the same timing on recognition of revenue but different commission rate. The one-time distribution commissions are earned and recognized when each individual investment is made, while the commission payments received from the product issuers are made in accordance with payment schedule agreed between the Group and the product issuer, which is usually less than three months after the end of the fund-raising period. 2. Insurance brokerage service The Group provides insurance brokerage service distributing insurance on behalf of the insurance agency companies and charges insurance agency companies for brokerage service commissions. The Group enters into insurance brokerage service contracts with insurance agency companies to specify key terms and conditions of each arrangement, which among other things, include a pre-agreed one-time commission entitled by the Group in exchange for its sales facilitation service provided to the insurance agency companies. These commissions are normally calculated as a percentage (which varies depending on the type of insurance products involved) of the premium to the insurance companies from sales facilitated by the Group in respect of an insurance product. 2.1 Initial placement of an insurance policy Insurance brokerage services are considered to be rendered and completed, and revenue is recognized, at the time an insurance policy becomes effective, that is, when the signed insurance policy is in place and the premium is collected by the insurance companies from the insured. The Group has satisfied the performance obligation to recognize revenue when the premiums are collected by the respective insurance companies and not before, because collectability is not ensured until receipt of the premium. Accordingly, the Group does not accrue any insurance brokerage service commission and fees prior to the receipt of the related premiums. For insurance products, there is generally a 10 to 15 days hesitation or clawback period after an initial placement of an insurance policy. During hesitation or clawback period, the insured has a legal right to unconditionally cancel the effective policy regardless of the reasons. The clawback provision entitled the insurance companies and brokers to recall any payment previously paid to the Group or to set off against any future payment. The revenues are reversed once clawback occurred. During the years ended June 30, 2021, 2022 and 2023, there were revenue amounted to RMB 0.17 million, RMB 0.25 million and RMB 0.61 million subject to clawback. The Group evaluates and updates its estimates of the clawback provision of each contract at each reporting date, based on historical experiences and various other assumptions that the Group believes to be reasonable under the circumstances and concludes that the occurrence of clawback from insurance companies and brokers are considered remote. The commission payment term from insurance agency companies is normally on a semi-month basis, with payment paid within 6-26 days after the amount of service fee of previous statement was confirmed by both parties. 2.2 Renewals of an insurance policy For the long-term insurance products, in addition to the initial commission earned, the Group is also entitled to subsequent renewal commission and compensation, and renewal performance bonus which represent variable considerations and are contingent on future renewals of initial policies or the Group achieves its performance target. Renewal commissions are determined by multiplying a pre-agreed charge rate with renewal premiums actually paid by the policyholders. Renewal compensation is determined by multiplying a pre-agreed charge rate with certain insurance products’ renewal premiums actually paid by the policyholders. Renewal performance bonus is variable according to different threshold of the total renewal premiums. When making estimates of the amount of variable consideration to which the Group expects to be entitled, the Group uses the expected value method and evaluates many factors, including but not limited to, insurance companies mix, product mix, renewal term of various products, renewal premium rates and commission rates, to determine the method(s) of measurement, relevant inputs and the underlying assumptions. The Group considers constraints as well when determining the amount which should be included in the transaction price. For fiscal years prior to 2023, revenue related to the variable consideration is recorded when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur, i.e., when a policyholder pays the renewal premium to the insurance company, and the policy is renewed because the Group was not able to conclude a significant reversal to the estimated variable consideration is not probable, considering factors such as a) the Group has limited history of selling its current insurance products with its current customers, such that the Group’s past experience in outdated products is of little predictive value in renewal(s) rate estimate; b) the occurrence of a renewal is outside the Group’s control and the estimate of renewal premium rates is complex and requires significant assumptions; and c) the contingency lasts across a long period of time. The Group performs ongoing evaluation of the appropriateness of the constraint applied, and will consider the sufficiency of evidence that would suggest that the long-term expectation underlying the assumptions has changed. Starting from July 1, 2022 the Group believes that it has already accumulated adequate scale of historical data and experiences at a confidence level that through which the Group can utilize to make a reasonable estimate of variable considerations over its portfolio of contracts. The estimated renewal commissions are contingent on future renewals of initial policies or achievement of certain performance targets. Given the material uncertainty around the future renewal of the insurance policies, the estimated renewal commissions expected to be collected are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty is subsequently resolved. The judgment and assumptions are continuously re-evaluated and adjusted as needed along with the accumulation of historical experiences and data when new information becomes available. Actual renewal commissions in the future may differ significantly from those previously estimated. For the year ended June 30, 2021, 2022 and 2023, the Group recognized revenues related to estimated variable renewal commissions with respect to long-term insurance products amounting to nil, nil and RMB33,491, respectively. Performance-based income In some of the Group’s fund distribution arrangements, the Group is also entitled to a performance-based income, which is based on the extend by which the related fund’s investments performance exceeds a hurdle rate. Such performance-based fees are a form of variable consideration, and are typically calculated and distributed when the cumulative return of the fund can be determined. Such performance-based income is typically recognized as revenues at a point in time, usually when the fund liquidates and the cumulative return of the fund can be determined. The Group does not bear any loss from the investors’ investments nor provides any guarantees of return with respect to the products it distributes. Over-time income In some of the Group’s fund distribution arrangements, the Group is also entitled to client maintenance fees. After the investors purchased the products, the Group has the obligation to perform customer account management, information books keeping, contracts storage and other daily maintenance duties. After the contract is established, there are no significant judgments made when determining the transaction price. As the Group provides these services throughout the contract term, revenue is calculated on daily basis over the contract term. The agreements do not include rights of return, credits or discounts, rebates, price protection or other similar privileges. Payment of client maintenance fees are normally on a regular basis (typically quarterly) and are not subject to clawback once determined. Asset management service Revenues generated from providing asset management service represents management fees and performance-based income the Group earns by serving as a fund manager. Management fees Management fees generated from the Group’s asset management services are earned from providing investment management service throughout the duration of various investment funds, which represents a performance obligation that is satisfied over time. Revenues of management fees are recognized over time on a monthly basis over the contract term, which is calculated in accordance with the respective fund contract or mandate agreement, either as a percentage of the total investments made by the investors or as a percentage of the fair value of the fund’s or mandate’s net assets, calculated regularly. The management fees do not include any rights of return, credits or discounts, rebates, price protection or other similar privileges, once determined. Performance-based income In a typical asset management arrangement in which the Group serves as a fund manager, beside management fee, the Group is also entitled to a performance-based fee based on the extent by which the fund’s investment performance exceeds a certain threshold. The performance-based fees earned by the Group are a form of variable consideration in the Group’s asset management contracts with customers. Such revenues of performance-based income from providing asset management service are recognized at a point in time when the performance of the fund can be determined. Health management service The Group offers medical examination, chronic disease management, immune system enhancement, and anti-aging solutions to our clients. The Group renders such services at the request of its customers. The Group recognizes revenues when it satisfies a performance obligation by transferring a promised good or service to a customer, such as examination reports are issued and passed to the customer or acceptance form is signed by the customer for the treatment service and products served and received by the customer. For most of corporate customers, fees are collected after the completion of the services while most of individual customers’ fees are collected before the performance of the services. The Group records accounts receivables from its corporate customers when revenues are recognized. Contracts with customers may contain multiple performance obligations that are distinct and are accounted for separately. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Group determines standalone selling price for all performance obligations using observable inputs, which is the amount the Group charges for that performance obligation if it were sold separately in a standalone sale, and the price the Group would sell to similar customers in similar circumstances. Others Revenue generated from others mainly represents referral service fee for oversea property purchases and information technology service fee for providing transaction process management service to fund managers. These revenues are recognized at a point in time based on the value of property purchased and the fund-raising amount of the products. Contract balances The Group’s contract balances include accounts receivable, contract assets and contract liabilities. The balances of accounts receivable as of June 30, 2022 and 2023 are all derived from contracts with customers. The Group classifies its right to consideration in exchange for products or services transferred to a customer as either a receivable or a contract asset. A receivable is a right to consideration that is unconditional as compared to a contract asset which is a right to consideration that is conditional upon factors other than the passage of time. Generally, the amount of revenue recognized from insurance brokerage services exceeds the amount billed to customers following the predetermined premium payment schedules at inception of the insurance policy. The Group does not have an unconditional right to such exceeding amount. Accounts receivable represent the considerations for which the Group has satisfied its performance obligations and has the unconditional right to consideration. At each reporting date, the Group assesses whether there is any indicator of impairment to the contract assets and accounts receivable. When the insurance policy is renewed, correspondent contract assets converted into accounts receivable. A contract liability is recognized when the Group has an obligation to transfer products or services to a customer for which the Group has received consideration from the customer, or for which an amount of consideration is due from the customer. Contract liabilities are included in advances from customers on the consolidated balance sheets. The following tables present the Group’s revenues disaggregated by service line and timing of revenue recognition: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2021 ​ ​ Wealth ​ Asset ​ ​ ​ Total Net ​ Management Management Others Revenues ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues recognized at a point in time 1,795,552 1,322 ​ 23,928 ​ 1,820,802 Revenues recognized over time — 13,620 ​ — ​ 13,620 Total 1,795,552 14,942 ​ 23,928 ​ 1,834,422 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ Wealth ​ Asset ​ Health ​ ​ ​ Total Net ​ Management Management Management Others Revenues ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ RMB ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues recognized at a point in time 1,871,958 171 422 ​ 22,642 ​ 1,895,193 Revenues recognized over time 27,615 19,305 — ​ — ​ 46,920 Total 1,899,573 19,476 422 ​ 22,642 ​ 1,942,113 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ Wealth ​ Asset ​ Health ​ ​ ​ Total Net ​ Management Management Management Others Revenues ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ RMB ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues recognized at a point in time 1,901,207 658 ​ 86,464 ​ 23,321 ​ 2,011,650 Revenues recognized over time 48,203 31,904 ​ — ​ — ​ 80,107 Total 1,949,410 32,562 ​ 86,464 ​ 23,321 ​ 2,091,757 Amounts in US$ 280,777 4,690 ​ 12,454 ​ 3,359 ​ 301,280
Compensation and benefit	t) Compensation and benefit Compensation and benefits primarily include base salary, sales commission and other compensation and benefits of the Group’s relationship managers, who directly contribute to the Group’s revenues generation activities, such as distribution of fund products and insurance products for wealth management and asset management service. Unpaid commissions were separately presented as commission payable and commission payable-long term on the Group’s consolidated balance sheets, depending on whether the amounts are expected to be paid within or after one year of each reporting date.
Health management cost	u) Health management cost Health management cost consist of expenditures incurred in the generation of the Group’s revenues from health management service, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers.
Income taxes	v) Income taxes The Group follows the guidance of ASC Topic 740 “Income taxes” and uses asset and liability method to account for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets, if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized in statement of income and comprehensive income in the period that includes the enactment date.
Uncertain tax positions	w) Uncertain tax positions The Group uses a more likely than not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result, the impact of an uncertain income tax position is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest on non-payment of income taxes under requirement by tax law and penalties associated with tax positions when a tax position does not meet the minimum statutory threshold to avoid payment of penalties recognized, if any, will be classified as a component of the provisions for income taxes. The tax returns of the Group’s Hong Kong and PRC subsidiaries and VIEs are subject to examination by the relevant local tax authorities. According to the Departmental Interpretation and Practice Notes No.11 (Revised) (“DIPN11”) of the Hong Kong Inland Revenue Ordinance (the “HK tax laws”), an investigation normally covers the six years of the assessment prior to the year of the assessment in which the investigation commences. In the case of fraud and willful evasion, the investigation is extended to cover ten years of assessment. According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances, where the underpayment of taxes is more than RMB100,000. In the case of transfer pricing issues, the statute of limitation is ten years. There is no statute of limitation in the case of tax evasion. For the years ended June 30, 2021, 2022 and 2023, the Group did not have any material interest or penalties associated with tax positions. The Group did not have any significant unrecognized uncertain tax positions as of June 30, 2022 or 2023. The Group does not expect that its assessment regarding unrecognized tax positions will materially change over the next 12 months. For the years ended June 30, 2021, 2022 and 2023, the Group do not have any entity that is under tax examination.
Share-based compensation	x) Share-based compensation The Group’s share-based payment transactions with employees are measured based on the grant-date fair value of the instruments, with recognition of either a corresponding increase in equity or a liability, depending on whether the instruments granted satisfy the equity or liability classification criteria. The fair value of the award is recognized as compensation expense, net of estimated forfeitures, over the period during which an employee is required to provide service in exchange for the award on straight line basis, which is generally the vesting period. Refer to Note 19 for details.
Segment reporting	y) Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (the “CODM”), which is comprised of chief executive officer of the Group’s management team. Consequently, as of June 30, 2022 and 2023, the Group operated two segments: (1) the wealth segment, which mainly consists of providing wealth management, asset management, insurance brokerage, other financial services to clients, and (2) the health segment, which consists of providing health management services to clients.
Earnings per share	z) Earnings per share Basic earnings per share is computed by dividing income attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings per share reflect the potential dilution that could occur if securities or other contracts to issue ordinary shares were exercised or converted into ordinary shares. Ordinary shares issuable upon the conversion of the convertible preferred shares are included in the computation of diluted earnings per share on an “if-converted” basis when the impact is dilutive.
Commitments and contingencies	aa) Commitments and contingencies The Group accrues estimated losses from loss contingencies by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an asset had been impaired, or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred. As of June 30, 2022 and 2023, the Group recognized nil and RMB1,034 contingent liabilities, respectively, relating to litigations against Hywin Wealth Management Co., Ltd. (Hywin Wealth Management) and Grand Doctor. Contingent liabilities recognized by the Group were included in the Group’s other payables and accrued liabilities account.
Comparative information	bb) Comparative information Certain items in prior years consolidated financial statements have been reclassified to conform to the current period’s presentation to facilitate comparison.
Recent issued or adopted accounting standards	cc) Recent issued or adopted accounting standards In November 2021, the FASB issued ASU 2021-10, “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance”, which provides guidance on the disclosure of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The new guidance is required to be applied either prospectively to all transactions within the scope of ASU 2021-10 that are reflected in financial statements at the date of adoption and new transactions that are entered into after the date of adoption or retrospectively to those transactions. This guidance is effective for the Company from July 1, 2022. The adoption of the guidance has no material impact on the financial position, results of operations and cash flows. In June 2016, the FASB issued ASU No.2016-13, “Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”. The amendments in this ASU require the measurement and recognition of expected credit losses for financial assets held at amortized cost. The amendments in this ASU replace the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. In November 2018, the FASB issued ASU No. 2018-19, “Codification Improvements to Topic 326, Financial Instruments-Credit Losses”, which among other things, clarifies that receivables arising from operating leases are not within the scope of Subtopic 326-20. Instead, impairment of receivables arising from operating leases should be accounted for in accordance with Topic 842, Leases. For public entities, the amendments in these ASUs are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For all other entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021. As a result of the issuance of ASU No. 2019-10 as discussed above, the effective date of ASU No. 2016-13 and its subsequent updates for all other entities was deferred to for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Group will adopt ASU 2016-13 from July 1, 2023. The Group does not expect that the adoption will have material impact on the Company’s financial position, results of operations and cash flows.

Organization (Tables)

Organization (Tables)	12 Months Ended
	Jun. 30, 2023
Organization
Schedule of detailed information of the Group's consolidated subsidiaries, VIEs and significant VIEs' subsidiaries	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Date of ​ Percentage of ​ Place of ​ ​ Name of the entity incorporation ownership incorporation Principle business activities ​ ​ ​ ​ ​ ​ ​ ​ ​ Subsidiaries ​ ​ ​ ​ ​ ​ ​ ​ Hywin Wealth Global Limited ​ July 26, 2019 100 % BVI Investment holding Hywin Wealth International Limited ​ August 20, 2019 100 % Hong Kong Investment holding Hywin Enterprise Management Consulting (Shanghai) Co., Ltd. ​ September 26, 2019 100 % PRC Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Variable Interest Entities (“VIEs”) ​ Hywin Wealth Management Co., Ltd. ​ November 2, 2006 100 % PRC Investment holding and provision of wealth management service Shanghai Hywin Network Technology Co., Ltd. ​ March 31, 2017 100 % PRC Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Shenzhen Panying Asset Management Co., Ltd. ​ May 23, 2014 100 % PRC Provision of asset management service ​ ​ ​ ​ ​ ​ ​ ​ ​ VIEs’ significant subsidiaries ​ Hywin Fund Distribution Co., Ltd. ​ April 17, 2013 100 % PRC Provision of wealth management service Shanghai Ziji Information Technology Co., Ltd. ​ November 24, 2017 100 % PRC Provision of information technology support Haiyin Wealth Management (Hong Kong) Limited ​ May 3, 2016 100 % Hong Kong Investment holding and provision of insurance brokerage service Haiyin Insurance (Hong Kong) Co., Limited ​ August 24, 2016 100 % Hong Kong Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Hywin International Insurance Broker Limited ​ March 23, 2006 100 % Hong Kong Provision of insurance brokerage service Haiyin International Asset Management Limited ​ September 15, 2016 100 % Hong Kong Investment holding ​ ​ ​ ​ ​ ​ ​ ​ ​ Hywin Asset Management (Hong Kong) Limited ​ January 9, 2013 100 % Hong Kong Provision of wealth management and asset management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Yulan Real Estate Co., Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Suxiao Real Property Co., Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Danxiao Real Property Co. Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Shanghai Biyu Real Property Co., Ltd. ​ December 9,2021 ​ 100% ​ PRC ​ Housing lease operation, and property management services ​ ​ ​ ​ ​ ​ ​ ​ ​ Hywin Health Management (Shanghai) Co., Ltd ​ September 15,2021 ​ 100% ​ PRC ​ Investment holding and provision of health management service ​ ​ ​ ​ ​ ​ ​ ​ ​ Grand Doctor Medical Co., Ltd. ​ January 27, 2022 ​ 65.3% ​ PRC ​ Provision of health management service ​ ​ ​ ​ ​ ​ ​ ​ ​ Beijing iLife 3 Technology Co., Ltd. ​ August 25, 2022 ​ 63.39% ​ PRC ​ Provision of health management service ​ ​ ​ ​ ​ ​ ​ ​ ​ Sincerity and Compassion Health Management Center ​ September 1, 2022 ​ 65% ​ PRC ​ Provision of health management service

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	12 Months Ended
	Jun. 30, 2023
Variable Interest Entities
Summary of balances and amounts of the VIEs included in the Group's consolidated financial statements	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ (RMB) ​ (RMB) ​ (US$) ​ ​ ​ ​ ​ ​ ​ Total Assets 1,609,296 ​ 2,243,526 ​ 310,488 Total liabilities 784,499 ​ 1,183,705 ​ 163,816 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ ​ (RMB) ​ (RMB) ​ (RMB) ​ (US$) ​ ​ ​ ​ ​ ​ ​ ​ ​ Net revenues 1,834,422 ​ 1,942,113 ​ 2,091,757 ​ 301,280 Net income 207,662 ​ 239,445 ​ 131,222 ​ 18,900 Cash flow provided by operating activities 334,038 ​ 242,326 ​ 525,229 ​ 75,650 Cash flow used in investing activities (14,631) ​ (286,497) ​ (201,099) ​ (28,965) Cash flow provided by/(used in) financing activities 4,895 ​ (1,000) ​ 1,568 ​ 226 ​

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies
Summary of aging schedule of the accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Less than 3 months 450,326 ​ 404,295 ​ 55,952 More than 3 months and less than 1 year 111,049 ​ 7,468 ​ 1,033 More than 1 year 2,999 ​ 3,371 ​ 467 Total 564,374 ​ 415,134 ​ 57,452
Summary of roll forward schedule of accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ Amount ​ RMB US$ Balance as of June 30, 2021 594,061 ​ 91,958 Revenue (including VAT) 2,055,534 ​ 318,352 Collections (2,085,221) ​ (326,218) Balance as of June 30, 2022 564,374 ​ 84,092 Acquisition of Life Infinity & SCHMC ​ 7,715 ​ 1,125 Revenue (including VAT) 2,197,657 ​ 316,533 Collections (2,354,648) ​ (344,298) Balance as of June 30, 2023 415,134 ​ 57,452
Summary of estimated useful lives of property and equipment	​ ​ ​ ​ Real estate property 14 years Leasehold improvements Shorter of the remaining lease terms and estimated useful lives Electronic equipment 3- 16 Furniture, fixture and other equipment ​ 3- 14 Motor Vehicles 5 years
Schedule of estimated useful lives of intangible assets	​ ​ ​ ​ Software 3 Trademark 7 10 Customer relationship 10 years License indefinite life
Summary of revenues disaggregated by service line and timing of revenue recognition	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2021 ​ ​ Wealth ​ Asset ​ ​ ​ Total Net ​ Management Management Others Revenues ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues recognized at a point in time 1,795,552 1,322 ​ 23,928 ​ 1,820,802 Revenues recognized over time — 13,620 ​ — ​ 13,620 Total 1,795,552 14,942 ​ 23,928 ​ 1,834,422 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ Wealth ​ Asset ​ Health ​ ​ ​ Total Net ​ Management Management Management Others Revenues ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ RMB ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues recognized at a point in time 1,871,958 171 422 ​ 22,642 ​ 1,895,193 Revenues recognized over time 27,615 19,305 — ​ — ​ 46,920 Total 1,899,573 19,476 422 ​ 22,642 ​ 1,942,113 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 ​ ​ Wealth ​ Asset ​ Health ​ ​ ​ Total Net ​ Management Management Management Others Revenues ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ RMB ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues recognized at a point in time 1,901,207 658 ​ 86,464 ​ 23,321 ​ 2,011,650 Revenues recognized over time 48,203 31,904 ​ — ​ — ​ 80,107 Total 1,949,410 32,562 ​ 86,464 ​ 23,321 ​ 2,091,757 Amounts in US$ 280,777 4,690 ​ 12,454 ​ 3,359 ​ 301,280

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jun. 30, 2023
Grand Doctor Medical Co., Ltd
Business Acquisition [Line Items]
Summary of allocation of purchase price to the major classes of assets and liabilities acquired	The table below presented the allocation of purchase price to the major classes of assets and liabilities acquired as of January 27, 2022: ​ ​ ​ ​ ​ ​ Amount Allocated ​ ​ RMB US$ Identifiable assets acquired and liabilities assumed Cash and cash equivalents 3,736 557 Other current assets 21,897 3,263 Property and equipment and other non-current assets 23,486 3,499 Other current liabilities (19,413) (2,892) Acquired intangible assets: -- Internet Hospital License 3,600 536 -- Customer Relationship 2,600 387 Identifiable assets acquired and liabilities assumed (a) 35,906 5,350 Redeemable noncontrolling interest (b) 30,600 4,559 Consideration (c) 80,500 11,995 Goodwill (c+b-a) 75,194 11,204
Beijing iLife 3 Technology Co., Ltd.
Business Acquisition [Line Items]
Summary of allocation of purchase price to the major classes of assets and liabilities acquired	The table below presented the allocation of purchase price to the major classes of assets and liabilities acquired as of August 25, 2022: ​ ​ ​ ​ ​ ​ ​ ​ Amount Allocated ​ RMB US$ ​ ​ ​ ​ ​ Identifiable assets acquired and liabilities assumed ​ ​ ​ ​ Cash and cash equivalents ​ 6,905 ​ 956 Other current assets ​ 106,596 ​ 14,752 Property and equipment and other non-current assets ​ 19,569 ​ 2,708 Other current liabilities ​ (138,262) ​ (19,134) Acquired intangible assets: ​ ​ ​ ​ -- Trademark ​ 41,283 ​ 5,713 -- Internet Hospital License ​ 3,169 ​ 439 -- Customer Relationship ​ 22,684 ​ 3,139 Acquired deferred tax liability: ​ (16,784) ​ (2,323) Identifiable assets acquired and liabilities assumed (a) ​ 45,160 ​ 6,250 Noncontrolling interests(b) ​ 88,292 ​ 12,219 Consideration (c) ​ 141,232 ​ 19,546 Goodwill (c+b-a) ​ 184,364 ​ 25,515
Sincerity and Compassion Health Management Center
Business Acquisition [Line Items]
Summary of allocation of purchase price to the major classes of assets and liabilities acquired	The table below presented the allocation of purchase price to the major classes of assets and liabilities acquired as of September 1, 2022: ​ ​ ​ ​ ​ ​ ​ ​ Amount Allocated ​ RMB US$ ​ ​ ​ ​ ​ Identifiable assets acquired and liabilities assumed ​ ​ ​ ​ Cash and cash equivalents ​ 73 ​ 10 Other current assets ​ 2,707 ​ 375 Property and equipment and other non-current assets ​ 34,007 ​ 4,706 Other current liabilities ​ (7,400) ​ (1,024) Acquired intangible assets: ​ ​ ​ ​ -- Trademark ​ 3,490 ​ 483 -- ​ 2,572 ​ 356 Acquired deferred tax liability: ​ (1,515) ​ (210) Identifiable assets acquired and liabilities assumed (a) ​ 33,934 ​ 4,696 Noncontrolling interests(b) ​ 18,750 ​ 2,595 Consideration (c) ​ 48,750 ​ 6,747 Goodwill (c+b-a) ​ 33,566 ​ 4,645

Deposits, Prepayments and Oth_2

Deposits, Prepayments and Other Current Assets (Tables)	12 Months Ended
	Jun. 30, 2023
Deposits, Prepayments and Other Current Assets
Schedule of deposits, prepayments and other current assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Deposits for office spaces leases 24,852 25,819 3,573 Prepaid property management fee 16,975 ​ 2,540 ​ 352 Other current assets 9,377 ​ 18,033 ​ 2,495 ​ 51,204 ​ 46,392 ​ 6,420 6. ​

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Jun. 30, 2023
Property and Equipment, net
Schedule of property and equipment, net	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Real estate property (1) ​ 300,757 ​ 300,757 ​ 41,623 Leasehold improvements 133,163 177,436 24,556 Electronic equipment 66,590 113,425 15,697 Furniture, fixtures and other equipment 21,840 22,027 3,048 Motor vehicles 2,533 2,533 351 Property and equipment, cost 524,883 616,178 85,275 Less: accumulated depreciation (199,771) (266,493) (36,881) ​ 325,112 349,685 48,394 (1) On December 9, 2021, the Group entered into a Share Purchase Agreement to purchase 100% equity interest of Shanghai Yulan Real Property Co., Ltd., Shanghai Suxiao Real Property Co., Ltd., Shanghai Danxiao Real Property Co. Ltd., and Shanghai Biyu Real Property Co., Ltd. (collectively refer to as the “Real Property Companies”), who are the owners of 3rd and 4th floor of No. 8, Yincheng Middle Road (the “Property”), the Group’s current principal office. The current principal office was leased from the Real Property Companies before the acquisition. The consideration for acquiring the Real Property Companies is RMB36,338 cash as well as the assumption of liabilities of Real Property Companies of RMB273,950 to a third party. There is no noncash or contingent consideration. As of June 30, 2023, the Group has paid full amount of the cash consideration and RMB200,000 liabilities assumed in this acquisition to a third party. The acquisition is accounted as an asset acquisition since substantially all the fair value of the gross assets acquired is concentrated in a single group of identifiable assets. The excess of consideration over fair value of the assets acquired was allocated to property and equipment.

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Jun. 30, 2023
Intangible Assets, Net
Schedule of intangible assets, net	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ Computer software 28,478 34,547 4,782 Licenses 15,648 16,673 2,307 Internet Hospital License ​ 3,600 ​ 6,769 ​ 937 Customer Relationship ​ 2,600 ​ 27,857 ​ 3,855 Trademark ​ — ​ 44,773 ​ 6,196 Intangible assets, cost 50,326 130,619 18,077 Less: accumulated amortization (16,778) (29,806) (4,125) accumulated impairment ​ — ​ (2,210) ​ (306) ​ 33,548 98,603 13,646

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Jun. 30, 2023
Goodwill.
Schedule of changes in the carrying amount of goodwill	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Grand Life ​ ​ ​ ​ ​ Doctor ​ Infinity ​ SCHMC ​ Total ​ Total ​ ​ RMB ​ RMB ​ RMB ​ RMB ​ US$ Balance as of June 30, 2021 — — — — — Additions 75,194 — — 75,194 11,204 Balance as of June 30, 2022 75,194 — — 75,194 11,204 Additions — 184,364 33,566 217,930 30,160 Impairment (35,412) — — (35,412) (5,100) Exchange translation adjustment — — — — (598) Balance as of June 30, 2023 39,782 184,364 33,566 257,712 35,666

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2023
Leases
Schedule of operating lease right-of-use assets and lease liabilities, and the associated financial statement line items	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ ​ RMB ​ RMB ​ US$ Assets Operating lease right-of-use assets, net — 186,307 25,784 ​ ​ ​ ​ ​ ​ ​ Liabilities Operating lease liabilities, current — 83,573 11,566 Operating lease liabilities, non-current — 100,521 13,911
Schedule of information related to operating lease activities	​ ​ ​ ​ ​ ​ ​ ​ For the year ended ​ June 30, 2023 ​ ​ RMB US$ Operating lease expense ​ ​ ​ ​ Amortization of right-of-use assets 76,696 11,047 Interest of lease liabilities 9,113 1,313 Short term lease expense 4,069 586 Total 89,878 12,946
Schedule of operating lease commitment	​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2023 2023 ​ ​ RMB ​ US$ Twelve months ending June 30, 2024 98,941 13,693 2025 51,671 7,151 2026 24,003 3,322 2027 16,954 2,346 2028 10,770 1,490 Thereafter 3,953 547 Total lease payments 206,292 28,549 Less: imputed interest (22,198) (3,072) Total 184,094 25,477 10. ​
Schedule of supplemental cash flow information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ ​ RMB RMB RMB US$ Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases — — 77,887 11,218 ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental noncash information: — — Effect on operating assets upon the adoption of ASU 2016-13 on July 1, 2022 — — 204,296 29,425 ​ ​ ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease obligations, net of decrease of right-of-use assets for early terminations — — 48,572 6,996 ​ ​ ​ ​ ​ ​ ​ ​ ​ Transfer of prepayment of other liabilities to lease liabilities upon the adoption of ASU 2016-13 on July 1, 2022 — — 10,135 1,460

Consideration payable and oth_2

Consideration payable and other payables (Tables)	12 Months Ended
	Jun. 30, 2023
Consideration payable and other payables
Schedule of consideration payable and other payables	​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ ​ 2022 ​ 2023 ​ 2023 ​ RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ Value added tax and other taxes payable 225,598 245,381 ​ 33,959 Accrued payroll ​ 59,834 ​ 81,158 ​ 11,232 Service fee payables ​ 2,710 ​ 3,479 ​ 481 Payables related to property management fee ​ 12,102 ​ 1,287 ​ 178 Contingent liabilities related to legal proceedings ​ — ​ 1,034 ​ 143 Equity purchase payable (1) ​ 19,290 ​ 3,990 ​ 552 Payables related to the real property companies (2) ​ 73,950 ​ 73,950 ​ 10,234 Other current liabilities ​ 12,644 ​ 22,938 ​ 3,175 ​ ​ 406,128 ​ 433,217 ​ 59,954 (1) As of June 30, 2022, this amount represented the cash consideration payable to a third party for the acquisition of Grand Doctor (Note 4) of RMB 15,300 , which has been paid off in July 2022 as well as the cash consideration payable of RMB 3,990 to a third party for the acquisition of Shanghai Ziji in May 2020. As of June 30, 2022, this amount represented the cash consideration payable to a third party for the acquisition of Shanghai Ziji of RMB 3,990 in May 2020. (2) On December 9, 2021, Hywin Wealth Management Co., Ltd. acquires Shanghai Yulan Real Property Co., Ltd., Shanghai Suxiao Real Property Co., Ltd., Shanghai Danxiao Real Property Co. Ltd. and Shanghai Biyu Real Property Co., Ltd. (collectively refer to as the “Real Property Companies”). The Group took over the liabilities from the real property companies to a third party. The payables related to the real property companies amounted to RMB 73,950 , which is unsecured, interest free and payment on demand .

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2023
Income Taxes
Schedule of Group's Income/(Loss) before tax	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ ​ RMB ​ RMB ​ RMB ​ US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ PRC 308,685 333,425 97,057 13,979 HK (12,929) (10,009) 95,720 13,787 Cayman and others (5) 1,031 (1,127) (162) ​ 295,751 324,447 191,650 27,604
Schedule of income tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current (86,367) (88,861) (73,221) (10,546) Deferred (1,727) 283 1,841 265 ​ (88,094) (88,578) (71,380) (10,281)
Schedule of reconciliation of the income tax expense between PRC statutory income tax rate and actual income tax expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income before income tax expense 295,751 324,447 191,650 27,604 ​ PRC statutory income tax rate 25 % 25 % 25 % 25 % Income tax at PRC statutory income tax rate (73,938) (81,112) (47,912) (6,901) ​ Impact of different tax rates in other jurisdictions (1,100) (969) 7,853 1,131 ​ Preferential tax treatments and tax holiday effects (73) 1,110 2,578 371 ​ Super deduction of qualified R&D expenditures 13 173 251 36 ​ Expenses not deductible (including expenses accrued for share-based compensation amounting to RMB5,487, RMB1,835 and RMB1,302 for the years ended June 30, 2021, 2022 and 2023, respectively) (9,737) (3,011) (5,662) (816) ​ Valuation allowance on deferred tax assets (3,259) (4,769) (19,635) (2,827) ​ Tax effect on Impairment loss of goodwill ​ — ​ — ​ (8,853) ​ (1,275) ​ Income tax expense (88,094) (88,578) (71,380) (10,281) ​
Schedule of deferred income tax liabilities and assets	​ ​ ​ ​ ​ Amount ​ RMB ​ ​ ​ Balance as of June 30, 2021 3,548 Decrease due to amortization of intangible assets (207) Increase due to acquisition ​ 651 Exchange translation adjustment 59 Balance as of June 30, 2022 ​ 4,051 Net deferred tax liabilities of June 30, 2022 ​ 3,400 Decrease due to amortization of intangible assets ​ (1,841) Increase due to acquisition ​ 18,300 Exchange translation adjustment ​ 169 Balance as of June 30, 2023 20,679 Net deferred tax liabilities as of June 30, 2023 ​ 20,028 Amount in US$ 2,772 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ Tax loss carry forward 17,094 51,373 7,110 Net operating losses acquired through Acquisition ​ 16,259 ​ 50,821 ​ 7,033 Others 324 588 82 Less, valuation allowance (32,301) (101,406) (14,034) Balance as of June 30, 2023 1,376 1,376 191 Net deferred tax assets as of June 30, 2023 ​ 725 ​ 725 ​ 100
Schedule of deferred tax assets valuation allowance	​ ​ ​ ​ ​ Amount ​ RMB ​ ​ ​ Balance as of June 30, 2021 12,271 Increase during the year ​ 4,769 Increase due to acquisition of entities ​ 15,206 Exchange translation adjustment ​ 55 Balance as of June 30, 2022 ​ 32,301 Increase during the year ​ 19,635 Increase due to acquisition of entities ​ 50,821 Decrease due to NOL expiration ​ (1,558) Exchange translation adjustment ​ 207 Balance as of June 30, 2023 ​ 101,406 Amount in US$ 14,034

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2023
Earnings Per Share
Schedule of basic and diluted earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ ​ 2021 ​ 2022 ​ 2023 ​ 2023 ​ ​ RMB RMB RMB US$ Numerator: ​ ​ ​ ​ ​ ​ ​ ​ Net income attributable to shareholders of Hywin Holdings Ltd. 207,657 235,869 129,881 18,707 Denominator: ​ ​ ​ ​ ​ ​ ​ ​ Denominator for basic earnings per share: Weighted average number of ordinary shares outstanding 51,528 56,000 56,000 56,000 Dilutive effect of outstanding share options 1,992 1,980 1,972 1,972 Denominator for diluted earnings per share 53,520 57,980 57,972 57,972 Basic earnings per share 4.03 4.21 2.32 0.33 Diluted earnings per share 3.88 4.07 2.24 0.32 Basic earnings per ADS 8.05 8.42 4.64 0.67 Diluted earnings per ADS 7.76 8.14 4.48 0.65 ​

Restricted Net Assets (Tables)

Restricted Net Assets (Tables) - Parent Company	12 Months Ended
	Jun. 30, 2023
Schedule of Balance Sheets	Balance Sheets (In thousands, except for share and per share data, or otherwise stated) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ (RMB) (RMB) (US$) ​ ​ ​ ​ ​ ​ ​ Assets Investments in subsidiaries and VIEs 968,313 1,111,691 153,850 Total Assets 968,313 1,111,691 153,850 Liabilities and Equity ​ ​ ​ ​ ​ ​ ​ Equity: Ordinary shares (US$0.0001 par value; authorized 500,000,000 shares; issued and outstanding 56,000,000 shares as of June 30, 2022 and 2023, respectively) 36 36 5 Additional paid-in capital 510,390 515,665 71,364 Accumulated gain 449,429 579,310 80,172 Accumulated other comprehensive income 8,458 16,680 2,309 Total equity 968,313 1,111,691 153,850 ​ ​ ​ ​ ​ ​ ​ Total Liabilities and Equity 968,313 1,111,691 153,850
Schedule of Statements of Operations	Statements of Operations (In thousands, except for share and per share data, or otherwise stated) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Share of income from subsidiaries and VIEs 207,657 235,869 129,881 18,707 Net income 207,657 235,869 129,881 18,707
Schedule of Statements of Cash Flows	Statements of Cash Flows (In thousands, except for share and per share data, or otherwise stated) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, ​ 2021 2022 2023 2023 ​ ​ RMB ​ RMB ​ RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest income ​ — ​ 791 ​ 93 ​ 13 Cash flows from operating activities — 791 93 13 Investment in subsidiaries ​ (180,677) ​ — ​ — ​ — Cash flows from investing activities (180,677) — — — Proceeds from issuance of ordinary shares from IPO ​ 180,677 ​ — ​ — ​ — Cash flows from financing activities 180,677 — — — Effect of exchange rate changes — — 64 — Net change in cash and cash equivalents — 791 157 13 Cash and cash equivalents at beginning of the year — — 791 118 Cash and cash equivalents at end of the year — 791 948 131 ​

Concentration of Risk (Tables)

Concentration of Risk (Tables)	12 Months Ended
	Jun. 30, 2023
Concentration of Risk
Summary of customer concentrations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ A B C D E F G H ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2023 Revenues, customer concentration risk * ​ * ​ — ​ 18 % 22 % * ​ 16 % * ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, customer concentration risk * ​ * ​ 13 % 14 % 10 % * ​ * * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Revenues, customer concentration risk 18 % 11 % * * — ​ — ​ * ​ * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 (1) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable (from third parties and related parties), customer concentration risk * * — * * * * 15 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 (1) ​ ​ ​ ​ ​ ​ ​ ​ Accounts receivable (from third parties and related parties), customer concentration risk * * * ​ 13 % 36 % 12 % * * ​ (1) The denominator for the calculation of accounts receivable, customer concentration risk was the total amount of accounts receivable from third parties, contract assets from third parties and accounts receivable from related parties as of June 30, 2022 and 2023, respectively. * Less than 10%.

Related Party Balances and Tr_2

Related Party Balances and Transactions (Tables)	12 Months Ended
	Jun. 30, 2023
Related Party Balances and Transactions
Schedule of significant related parties and their relationships with the Group	​ Name of the related parties Relation with the Group ​ ​ ​ Hywin Financial Holding Group Co., Ltd. (“Hywin Financial Holding”) An entity ultimately controlled by Mr. HAN Hongwei Ms. WANG Dian Senior executive officer Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I ​ Non-controlling interest shareholder of Grand Doctor ​ ​ Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II ​ Non-controlling interest shareholder of Grand Doctor ​ ​ Hywin Asset Management Co., Ltd. a direct subsidiary of Hywin Financial Holding Beijing Boyi Kangsheng Investment Consulting Co., Ltd Non-controlling interest shareholder of Life Infinity
Schedule of the related party balances	​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, ​ 2022 2023 2023 ​ RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ Amount due from related parties ​ ​ ​ ​ ​ ​ Amounts lent to a related party (1) : ​ ​ ​ ​ ​ Hywin Financial Holding Group Co., Ltd. (“Hywin Financial Holding”) 66,103 — — ​ ​ ​ ​ Due from related parties total 66,103 — — ​ ​ ​ ​ ​ ​ ​ ​ Amount due to related parties ​ ​ ​ ​ ​ ​ ​ Loans borrowed from and interest payable to related parties, net Wang Dian 1,891 1,891 262 Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I (4) 5,005 5,401 747 Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II (4) 6,370 6,874 951 Beijing Boyi Kangsheng Investment Consulting Co., Ltd ​ — ​ 1,000 ​ 138 Others ​ 406 ​ 407 ​ 57 ​ ​ 13,672 ​ 15,573 ​ 2,155 ​ ​ ​ ​ ​ ​ ​ Dividend payable to a related party: ​ ​ ​ ​ ​ Ms. Wang Dian 22,500 ​ 22,500 ​ 3,114 ​ ​ ​ ​ ​ ​ ​ Due to related parties-total 36,172 ​ 38,073 ​ 5,269 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended June 30, ​ 2021 2022 2023 2023 ​ RMB RMB RMB US$ ​ ​ ​ ​ ​ ​ ​ ​ ​ Wealth management services revenues from a related party Hywin Asset Management Co., Ltd. 3,144 4,499 1,679 241 ​ 3,144 4,499 1,679 241 Net loans borrowed from/lent to related parties (2) Loan lent to a related party, net ​ ​ ​ ​ ​ ​ ​ Hywin Financial Holding Group Co., Ltd. ​ 1,579 — — — ​ 1,579 — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collection of loans lent to related parties, net Hywin Financial Holding Group Co., Ltd. — 60,000 66,103 9,521 ​ — 60,000 66,103 9,521 ​ ​ ​ ​ ​ ​ ​ ​ ​ Loans borrowed from related parties, net ​ ​ ​ ​ Others 321 — — — ​ ​ 321 — — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loans and interest payables took over from acquiring Grand Doctor Medical Co., Ltd. (3) ​ ​ ​ ​ ​ ​ ​ ​ Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I — 4,840 — — Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II — 6,160 — — ​ — 11,000 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expenses charged by related parties Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I — 165 396 57 Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II — 210 504 73 ​ — 375 900 130 ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loans took over from acquiring Beijing iLife 3 Technology Co., Ltd. (4) Beijing Boyi Kangsheng Investment Consulting Co., Ltd — — 1,000 144 ​ — — 1,000 144

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Jun. 30, 2023
Share-based Compensation
Summary of the option activities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ ​ Remaining ​ Average ​ ​ ​ ​ Contractual ​ Exercise ​ Number of options Life (Years) Price (RMB) ​ ​ ​ ​ ​ ​ ​ Outstanding and exercisable, June 30, 2020 — — — Recognition of options originally under 2018 Option Plan and replaced by 2019 Option plan as of March 26, 2021 750,247 1.11 16.43 Recognition of new options granted under 2019 Option plan as of March 26, 2021 1,499,753 2.00 — Forfeited (235,613) — 0.74 Exercised ​ — ​ — ​ — Outstanding, June 30, 2021 2,014,387 1.48 5.29 Forfeited (102,084) — 1.21 Exercised — — — Outstanding, June 30, 2022 1,912,303 0.62 5.02 Forfeited ​ (28,500) ​ — ​ 1.27 Exercised ​ — ​ — ​ — Outstanding, June 30, 2023 ​ 1,883,803 ​ 0.15 ​ 5.03

Segment information (Tables)

Segment information (Tables)	12 Months Ended
	Jun. 30, 2023
Segment information
Summary of each segment's revenue, income from operations and net income	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, 2023 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Total net revenues ​ 2,005,293 ​ 87,841 ​ (1,377) ​ 2,091,757 ​ 301,280 Income from operations 308,530 (111,145) — 197,385 28,430 Net income/(loss) 231,419 (111,149) — 120,270 17,323 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, 2022 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Total net revenues 1,941,691 422 — 1,942,113 300,786 Income from operations 337,775 (11,085) — 326,690 50,596 Net income/(loss) 247,359 (11,490) — 235,869 36,530 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended June 30, 2021 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Total net revenues 1,834,422 — — 1,834,422 277,107 Income from operations 281,606 — — 281,606 42,539 Net income/(loss) 207,657 — — 207,657 31,369 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2023 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Goodwill — 257,712 — 257,712 35,666 Other assets 2,154,194 296,324 (334,738) 2,115,780 292,809 Total assets 2,154,194 554,036 (334,738) 2,373,492 328,475 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of June 30, 2022 ​ ​ Wealth Segment ​ Health Segment ​ Eliminated ​ Consolidated ​ Consolidated ​ ​ (RMB) (RMB) (RMB) (RMB) (US$) Goodwill — 75,194 — 75,194 11,204 Other assets 1,665,803 42,415 — 1,708,218 254,525 Total assets 1,665,803 117,609 — 1,783,412 265,729 ​

Organization (Details)

Organization (Details)	12 Months Ended
	Jun. 30, 2023
Hywin Wealth Global Limited
Organization
Percentage of ownership	100%
Hywin Wealth International Limited
Organization
Percentage of ownership	100%
Hywin Enterprise Management Consulting (Shanghai) Co., Ltd.
Organization
Percentage of ownership	100%
Hywin Wealth Management Co., Ltd.
Organization
Percentage of ownership	100%
Shanghai Hywin Network Technology Co., Ltd.
Organization
Percentage of ownership	100%
Shenzhen Panying Asset Management Co., Ltd.
Organization
Percentage of ownership	100%
Hywin Fund Distribution Co., Ltd.
Organization
Percentage of ownership	100%
Shanghai Ziji Information Technology Co., Ltd.
Organization
Percentage of ownership	100%
Haiyin Wealth Management (Hong Kong) Limited
Organization
Percentage of ownership	100%
Haiyin Insurance (Hong Kong) Co., Limited
Organization
Percentage of ownership	100%
Hywin International Insurance Broker Limited
Organization
Percentage of ownership	100%
Haiyin International Asset Management Limited
Organization
Percentage of ownership	100%
Hywin Asset Management (Hong Kong) Limited
Organization
Percentage of ownership	100%
Shanghai Yulan Real Estate Co., Ltd.
Organization
Percentage of ownership	100%
Shanghai Suxiao Real Property Co., Ltd.
Organization
Percentage of ownership	100%
Shanghai Danxiao Real Property Co. Ltd.
Organization
Percentage of ownership	100%
Shanghai Biyu Real Property Co., Ltd.
Organization
Percentage of ownership	100%
Hywin Health Management (Shanghai) Co., Ltd
Organization
Percentage of ownership	100%
Grand Doctor Medical Co., Ltd.
Organization
Percentage of ownership	65.30%
Beijing iLife 3 Technology Co., Ltd.
Organization
Percentage of ownership	63.39%
Sincerity and Compassion Health Management Center
Organization
Percentage of ownership	65%

Organization - Additional infor

Organization - Additional information (Details) - ADS	Mar. 26, 2021 $ / shares shares
Organization
Number of ordinary shares per ADS	2
IPO
Organization
Number of American depository shares issued	3,000,000
ADS price per share | $ / shares	$ 10
Number of ordinary shares per ADS	2

Variable Interest Entities (Det

Variable Interest Entities (Details)	12 Months Ended
	Jun. 30, 2023
Exclusive Technical Consultation and Service Agreements
Variable Interest Entities
Fee as a percentage of consolidated net income	100%
Term of agreement	20 years
Voting Right Proxy and Financial Support Agreements
Variable Interest Entities
Fee as a percentage of consolidated net income	100%
Term of agreement	20 years

Variable Interest Entities - Co

Variable Interest Entities - Consolidated Financial Statements (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2021 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Variable Interest Entities
Total Assets	¥ 2,373,492		¥ 1,783,412				$ 328,475	$ 265,729
Total liabilities	1,130,270		784,499				156,422
Net revenues	2,091,757	$ 301,280	1,942,113	$ 300,786	¥ 1,834,422	$ 277,107
Net income/(loss)	129,881	18,707	235,869		207,657
Cash flow provided by operating activities	525,322	75,663	238,751		334,033
Cash flow used in investing activities	(248,665)	(35,816)	(286,497)		(14,631)
Cash flow provided by/(used in) financing activities	1,568	226	(1,000)		185,606
Variable interest entity
Variable Interest Entities
Total Assets	2,243,526		1,609,296				310,488
Total liabilities	1,183,705		784,499				$ 163,816
Net revenues	2,091,757	301,280	1,942,113		1,834,422
Net income/(loss)	131,222	18,900	239,445		207,662
Cash flow provided by operating activities	525,229	75,650	242,326		334,038
Cash flow used in investing activities	(201,099)	(28,965)	(286,497)		(14,631)
Cash flow provided by/(used in) financing activities	¥ 1,568	$ 226	¥ (1,000)		¥ 4,895

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details)	Jun. 30, 2023 $ / ¥
Foreign currency translation and transactions
Exchange rate for balance sheet items, except equity	7.2258
Exchange rate for items in the statement of operation and comprehensive income, and statement of cash flow	6.9429

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Accounts receivable, net (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)
Accounts receivable, net
Total	¥ 415,134	$ 57,452	¥ 564,374
Less than 3 months
Accounts receivable, net
Total	404,295	55,952	450,326
More than 3 months and less than 1 year
Accounts receivable, net
Total	7,468	1,033	111,049
More than 1 year
Accounts receivable, net
Total	¥ 3,371	$ 467	¥ 2,999

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Roll forward schedule of accounts receivable (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)
Roll forward schedule of accounts receivable
Balance	¥ 564,374	$ 84,092	¥ 594,061	$ 91,958
Revenue (including VAT)	2,197,657	316,533	2,055,534	318,352
Collection	(2,354,648)	(344,298)	(2,085,221)	(326,218)
Acquisition of Life Infinity & SCHMC	7,715	1,125
Balance	415,134	$ 57,452	564,374	$ 84,092
Allowances for doubtful accounts	¥ 0		¥ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Property and equipment, net (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Property, Plant and Equipment
Loss from disposal of long-term assets	¥ 83	$ 12	¥ 22	¥ 81
Real estate property
Property, Plant and Equipment
Estimated useful lives	14 years	14 years
Electronic equipment | Minimum
Property, Plant and Equipment
Estimated useful lives	3 years	3 years
Electronic equipment | Maximum
Property, Plant and Equipment
Estimated useful lives	16 years	16 years
Furniture, fixture and other equipment | Minimum
Property, Plant and Equipment
Estimated useful lives	3 years	3 years
Furniture, fixture and other equipment | Maximum
Property, Plant and Equipment
Estimated useful lives	14 years	14 years
Motor Vehicles
Property, Plant and Equipment
Estimated useful lives	5 years	5 years

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Intangible assets, net (Details)	Jun. 30, 2023
Customer Relationship
Estimated useful lives of intangible assets
Estimated useful lives of intangible assets	10 years
Minimum | Software
Estimated useful lives of intangible assets
Estimated useful lives of intangible assets	3 years
Minimum | Trademark
Estimated useful lives of intangible assets
Estimated useful lives of intangible assets	7 years
Maximum | Software
Estimated useful lives of intangible assets
Estimated useful lives of intangible assets	5 years
Maximum | Trademark
Estimated useful lives of intangible assets
Estimated useful lives of intangible assets	10 years

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Impairment of long-lived assets (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥) item	Jun. 30, 2023 USD ($) item	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Impairment of long-lived assets
Impairment of indefinite-lived intangible assets	¥ 2,210	$ 318	¥ 0	¥ 0
Number of reporting units | item	4	4
Revenues related to estimated variable renewal commissions with respect to long-term insurance products	¥ 33,491		¥ 0	¥ 0
Impairment recognized on long-lived assets	¥ 0

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Impairment of goodwill and indefinite-lived intangible assets (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Summary of Significant Accounting Policies
Impairment loss of goodwill	¥ 35,412	$ 5,100	¥ 0	¥ 0

Summary of Significant Accou_11

Summary of Significant Accounting Policies - Insurance brokerage service (Details) - CNY (¥) ¥ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Revenue subject to clawback provision	¥ 610	¥ 250	¥ 170
Revenues related to estimated variable renewal commissions with respect to long-term insurance products	¥ 33,491	¥ 0	¥ 0
Minimum
Hesitation or clawback period after initial placement of an insurance policy (in days)	10 days
Commission payment term	6 days
Maximum
Hesitation or clawback period after initial placement of an insurance policy (in days)	15 days
Commission payment term	26 days

Summary of Significant Accou_12

Summary of Significant Accounting Policies - Others (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2021 USD ($)
Service line and timing of revenue recognition
Net revenues	¥ 2,091,757	$ 301,280	¥ 1,942,113	$ 300,786	¥ 1,834,422	$ 277,107
Revenues recognized at a point in time
Service line and timing of revenue recognition
Net revenues	2,011,650		1,895,193		1,820,802
Revenues recognized over time
Service line and timing of revenue recognition
Net revenues	80,107		46,920		13,620
Wealth Management
Service line and timing of revenue recognition
Net revenues	1,949,410	280,777	1,899,573		1,795,552
Wealth Management | Revenues recognized at a point in time
Service line and timing of revenue recognition
Net revenues	1,901,207		1,871,958		1,795,552
Wealth Management | Revenues recognized over time
Service line and timing of revenue recognition
Net revenues	48,203		27,615
Assets Management
Service line and timing of revenue recognition
Net revenues	32,562	4,690	19,476		14,942
Assets Management | Revenues recognized at a point in time
Service line and timing of revenue recognition
Net revenues	658		171		1,322
Assets Management | Revenues recognized over time
Service line and timing of revenue recognition
Net revenues	31,904		19,305		13,620
Health Management
Service line and timing of revenue recognition
Net revenues	86,464	12,454	422
Health Management | Revenues recognized at a point in time
Service line and timing of revenue recognition
Net revenues	86,464		422
Others
Service line and timing of revenue recognition
Net revenues	23,321	$ 3,359	22,642		23,928
Others | Revenues recognized at a point in time
Service line and timing of revenue recognition
Net revenues	¥ 23,321		¥ 22,642		¥ 23,928

Summary of Significant Accou_13

Summary of Significant Accounting Policies - Additional Information (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥) segment	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2020 CNY (¥)	Jun. 30, 2023 USD ($)
Summary of Significant Accounting Policies
Maximum amount of underpayment tax	¥ 100,000
Number of reportable operating segments | segment	2
Contingent liabilities	¥ 1,034	¥ 0			$ 143
Interest or penalties		0	¥ 0	¥ 0
Unrecognized tax positions		¥ 0	¥ 0

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) ¥ in Thousands, $ in Thousands				12 Months Ended
	Sep. 01, 2022 CNY (¥)	Aug. 25, 2022 CNY (¥)	Jan. 27, 2022 CNY (¥)	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Acquired intangible assets:
Acquisition consideration payable						¥ 15,300
Net income/(loss)				¥ 129,881	$ 18,707	235,869	¥ 207,657
Impairment loss of goodwill				35,412	$ 5,100	0	0
Grand Doctor Medical Co., Ltd
Acquired intangible assets:
Cash consideration			¥ 80,500
Equity interest acquired			65.26%
Acquisition consideration payable						15,300
Net revenues				9,835		422
Net income/(loss)				19,695		9,406
Impairment loss of goodwill				35,412		¥ 0	¥ 0
Beijing iLife 3 Technology Co., Ltd.
Acquired intangible assets:
Cash consideration		¥ 141,232
Equity interest acquired		63.39%
Net revenues				60,502
Net income/(loss)				14,017
Sincerity and Compassion Health Management Center
Acquired intangible assets:
Cash consideration	¥ 48,750
Equity interest acquired	65%
Net revenues				16,423
Net income/(loss)				¥ 8,430

Acquisitions - Allocation of pu

Acquisitions - Allocation of purchase price to the major classes of assets and liabilities acquired (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Sep. 01, 2022 CNY (¥)	Sep. 01, 2022 USD ($)	Aug. 25, 2022 CNY (¥)	Aug. 25, 2022 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jan. 27, 2022 CNY (¥)	Jan. 27, 2022 USD ($)
Acquired intangible assets:
Goodwill	¥ 257,712	$ 35,666					¥ 75,194	$ 11,204
Grand Doctor Medical Co., Ltd
Allocation of purchase price to the major classes of assets and liabilities acquired
Cash and cash equivalents									¥ 557	$ 3,736
Other current assets									3,263	21,897
Property and equipment and other non-current assets									3,499	23,486
Other current liabilities									(2,892)	(19,413)
Acquired intangible assets:
Identifiable assets acquired and liabilities assumed (a)									5,350	35,906
noncontrolling interests (b)									4,559	30,600
Consideration (c)									11,995	80,500
Goodwill	39,782						¥ 75,194		11,204	75,194
Grand Doctor Medical Co., Ltd | -- Internet Hospital License
Acquired intangible assets:
Acquired Intangible assets									536	3,600
Grand Doctor Medical Co., Ltd | Customer Relationship
Acquired intangible assets:
Acquired Intangible assets									¥ 387	$ 2,600
Beijing iLife 3 Technology Co., Ltd.
Allocation of purchase price to the major classes of assets and liabilities acquired
Cash and cash equivalents					¥ 6,905	$ 956
Other current assets					106,596	14,752
Property and equipment and other non-current assets					19,569	2,708
Other current liabilities					(138,262)	(19,134)
Acquired intangible assets:
Acquired deferred tax liability:					(16,784)	(2,323)
Identifiable assets acquired and liabilities assumed (a)					45,160	6,250
noncontrolling interests (b)					88,292	12,219
Consideration (c)					141,232	19,546
Goodwill	184,364				184,364	25,515
Beijing iLife 3 Technology Co., Ltd. | Trademark
Acquired intangible assets:
Acquired Intangible assets					41,283	5,713
Beijing iLife 3 Technology Co., Ltd. | -- Internet Hospital License
Acquired intangible assets:
Acquired Intangible assets					3,169	439
Beijing iLife 3 Technology Co., Ltd. | Customer Relationship
Acquired intangible assets:
Acquired Intangible assets					¥ 22,684	$ 3,139
Sincerity and Compassion Health Management Center
Allocation of purchase price to the major classes of assets and liabilities acquired
Cash and cash equivalents			¥ 73	$ 10
Other current assets			2,707	375
Property and equipment and other non-current assets			34,007	4,706
Other current liabilities			(7,400)	(1,024)
Acquired intangible assets:
Acquired deferred tax liability:			(1,515)	(210)
Identifiable assets acquired and liabilities assumed (a)			33,934	4,696
noncontrolling interests (b)			18,750	2,595
Consideration (c)			48,750	6,747
Goodwill	¥ 33,566		33,566	4,645
Sincerity and Compassion Health Management Center | Trademark
Acquired intangible assets:
Acquired Intangible assets			3,490	483
Sincerity and Compassion Health Management Center | Customer Relationship
Acquired intangible assets:
Acquired Intangible assets			¥ 2,572	$ 356

Deposits, Prepayments and Oth_3

Deposits, Prepayments and Other Current Assets (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)
Deposits, Prepayments and Other Current Assets
Deposits for office spaces leases	¥ 25,819	$ 3,573	¥ 24,852
Prepaid property management fee	2,540	352	16,975
Other current assets	18,033	2,495	9,377
Deposits, prepayments and other current assets	¥ 46,392	$ 6,420	¥ 51,204

Property and Equipment, net (De

Property and Equipment, net (Details) ¥ in Thousands, $ in Thousands		12 Months Ended
	Dec. 09, 2021 CNY (¥)	Jun. 30, 2023 CNY (¥)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2023 USD ($)
Property, Plant and Equipment
Property and equipment, cost		¥ 616,178	¥ 524,883		$ 85,275
Less: accumulated depreciation		(266,493)	(199,771)		(36,881)
Property and equipment, net		349,685	325,112		48,394
Depreciation		41,242	25,448	¥ 18,715
Assumption of liabilities		200,000
Impairment loss		0	0	¥ 0
Real Property Companies
Property, Plant and Equipment
Equity interest purchased	100%
Aggregate purchase consideration	¥ 36,338
Noncash or Contingent consideration	0
Assumption of liabilities	¥ 273,950
Real estate property
Property, Plant and Equipment
Property and equipment, cost		300,757	300,757		41,623
Leasehold improvements
Property, Plant and Equipment
Property and equipment, cost		177,436	133,163		24,556
Electronic equipment
Property, Plant and Equipment
Property and equipment, cost		113,425	66,590		15,697
Furniture, fixtures and other equipment
Property, Plant and Equipment
Property and equipment, cost		22,027	21,840		3,048
Motor vehicles
Property, Plant and Equipment
Property and equipment, cost		¥ 2,533	¥ 2,533		$ 351

Intangible Assets, Net (Details

Intangible Assets, Net (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2023 USD ($)
Finite-Lived Intangible Assets
Intangible assets, cost	¥ 130,619		¥ 50,326		$ 18,077
Less: accumulated amortization and impairment	(29,806)		(16,778)		(4,125)
Less: accumulated impairment	(2,210)				(306)
Intangible Assets, Net (Excluding Goodwill), Total	98,603		33,548		13,646
Amortization expenses	13,028		2,879	¥ 6,879
Impairment loss on intangible assets	2,210	$ 318	0	¥ 0
Computer software
Finite-Lived Intangible Assets
Intangible assets, cost	34,547		28,478		4,782
Licenses
Finite-Lived Intangible Assets
Intangible assets, cost	16,673		15,648		2,307
Internet Hospital License
Finite-Lived Intangible Assets
Intangible assets, cost	6,769		3,600		937
Customer Relationship
Finite-Lived Intangible Assets
Intangible assets, cost	27,857		¥ 2,600		3,855
Trademark [Member]
Finite-Lived Intangible Assets
Intangible assets, cost	¥ 44,773				$ 6,196

Goodwill - Changes in carrying

Goodwill - Changes in carrying amount of goodwill (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Sep. 01, 2022 CNY (¥)	Sep. 01, 2022 USD ($)	Aug. 25, 2022 CNY (¥)	Aug. 25, 2022 USD ($)	Jan. 27, 2022 CNY (¥)	Jan. 27, 2022 USD ($)
Goodwill
Beginning balance	¥ 75,194	$ 11,204
Additions	217,930	30,160	¥ 75,194	$ 11,204
Impairment	(35,412)	(5,100)	0		¥ 0
Exchange translation adjustment | $		(598)
Ending balance	257,712	$ 35,666	75,194	$ 11,204
Income tax expense	257,712		75,194
Grand Doctor Medical Co., Ltd
Goodwill
Beginning balance	75,194
Additions			75,194
Impairment	(35,412)		0		¥ 0
Ending balance	39,782		75,194
Income tax expense	39,782		¥ 75,194							¥ 11,204	$ 75,194
Life Infinity
Goodwill
Additions	184,364
Ending balance	184,364
Income tax expense	184,364							¥ 184,364	$ 25,515
SCHMC
Goodwill
Additions	33,566
Ending balance	33,566
Income tax expense	¥ 33,566					¥ 33,566	$ 4,645

Goodwill - Additional Informati

Goodwill - Additional Information (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Goodwill.
Impairment loss of goodwill	¥ 35,412	$ 5,100	¥ 0	¥ 0

Leases - Operating lease right-

Leases - Operating lease right-of-use assets and lease liabilities, and the associated financial statement line items (Details) - Jun. 30, 2023 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
Assets
Operating lease right-of-use assets, net	¥ 186,307	$ 25,784
Liabilities
Operating lease liabilities, current	83,573	11,566
Operating lease liabilities, non-current	¥ 100,521	$ 13,911
Weighted average remaining lease term (in years)	3 years 4 months 20 days	3 years 4 months 20 days
Weighted average discount rate (in percent)	4.45%	4.45%

Leases - Information related to

Leases - Information related to operating lease activities (Details) - 12 months ended Jun. 30, 2023 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
Operating lease expense
Amortization of right-of-use assets	¥ 76,696	$ 11,047
Interest of lease liabilities	9,113	1,313
Short term lease expense	4,069	586
Total	¥ 89,878	$ 12,946

Leases - Supplemental cash flow

Leases - Supplemental cash flow information (Details) - 12 months ended Jun. 30, 2023 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	¥ 77,887	$ 11,218
Supplemental noncash information:
Effect on operating assets upon the adoption of ASU 2016-13 on July 1, 2022	204,296	29,425
Right-of-use assets obtained in exchange for lease obligations, net of decrease of right-of-use assets for early terminations	48,572	6,996
Transfer of prepayment of other liabilities to lease liabilities upon the adoption of ASU 2016-13 on July 1, 2022	¥ 10,135	$ 1,460

Leases - Maturities of lease li

Leases - Maturities of lease liabilities (Details) - Jun. 30, 2023 ¥ in Thousands, $ in Thousands	CNY (¥)	USD ($)
Operating lease commitment
2024	¥ 98,941	$ 13,693
2025	51,671	7,151
2026	24,003	3,322
2027	16,954	2,346
2028	10,770	1,490
Thereafter	3,953	547
Total lease payments	206,292	28,549
Less: imputed interest	(22,198)	(3,072)
Total	¥ 184,094	$ 25,477

Consideration payable and oth_3

Consideration payable and other payables (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Dec. 09, 2021 CNY (¥)
Consideration payable and other payables
Value added tax and other taxes payable	¥ 245,381	$ 33,959	¥ 225,598
Accrued payroll	81,158	11,232	59,834
Service fee payables	3,479	481	2,710
Payables related to office rental and property management fee	1,287	178	12,102
Contingent liabilities related to legal proceedings	1,034	143	0
Equity purchase payable	3,990	552	19,290
Payables related to the real property companies	73,950	10,234	73,950	¥ 73,950
Other current liabilities	22,938	3,175	12,644
Consideration payable and other payables	¥ 433,217	$ 59,954	¥ 406,128

Consideration payable and oth_4

Consideration payable and other payables - Narrative (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2022 CNY (¥)	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Dec. 09, 2021 CNY (¥)
Consideration payable and other payables
Acquisition consideration payable	¥ 15,300
Payables related to the real property companies	73,950	¥ 73,950	$ 10,234	¥ 73,950
Cash consideration	¥ 3,990

Income Taxes (Details)

Income Taxes (Details) - HKD ($) $ in Millions	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax and Tax Rate
PRC statutory income tax rate	25%	25%	25%
HK
Income Tax and Tax Rate
PRC statutory income tax rate	16.50%
Preferential income tax rate	8.25%
Assessable profits threshold for preferential income tax rate	$ 2
PRC
Income Tax and Tax Rate
PRC statutory income tax rate	25%	25%	25%
Preferential income tax rate	12.50%

Income Taxes - Group's Income_(

Income Taxes - Group's Income/(Loss) before tax (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Income Tax and Tax Rate
Income before income tax expense	¥ 191,650	$ 27,604	¥ 324,447	¥ 295,751
PRC
Income Tax and Tax Rate
Income before income tax expense	97,057	13,979	333,425	308,685
HK
Income Tax and Tax Rate
Income before income tax expense	95,720	13,787	(10,009)	(12,929)
Cayman and others
Income Tax and Tax Rate
Income before income tax expense	¥ (1,127)	$ (162)	¥ 1,031	¥ (5)

Income Taxes - PRC subsidiaries

Income Taxes - PRC subsidiaries (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Income Taxes
Current	¥ (73,221)	$ (10,546)	¥ (88,861)	¥ (86,367)
Deferred	1,841	265	283	(1,727)
Income tax expense	¥ (71,380)	$ (10,281)	¥ (88,578)	¥ (88,094)

Income Taxes - PRC statutory in

Income Taxes - PRC statutory income tax rate (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Income Taxes
Income before income tax expense	¥ 191,650	$ 27,604	¥ 324,447	¥ 295,751
PRC statutory income tax rate	25%	25%	25%	25%
Income tax at PRC statutory income tax rate	¥ (47,912)	$ (6,901)	¥ (81,112)	¥ (73,938)
Impact of different tax rates in other jurisdictions	7,853	1,131	(969)	(1,100)
Preferential tax treatments and tax holiday effects	2,578	371	1,110	(73)
Super deduction of qualified R&D expenditures	251	36	173	13
Expenses not deductible (including expenses accrued for share-based compensation amounting to RMB5,487, RMB1,835 and RMB1,302 for the years ended June 30, 2021, 2022 and 2023, respectively)	(5,662)	(816)	(3,011)	(9,737)
Valuation allowance on deferred tax assets	(19,635)	(2,827)	(4,769)	(3,259)
Tax effect on Impairment loss of goodwill	(8,853)	(1,275)
Income tax expense	(71,380)	$ (10,281)	(88,578)	(88,094)
Expenses accrued (reversal) for share-based compensation	¥ 1,302		¥ 1,835	¥ 5,487

Income Taxes - Group's deferred

Income Taxes - Group's deferred tax liabilities (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2023 USD ($)
Income Taxes
Deferred tax liabilities, beginning balance	¥ 4,051	¥ 3,548
Decrease due to amortization of intangible assets	(1,841)	(207)
Increase due to acquisition	18,300	651
Exchange translation adjustment	169	59
Deferred tax liabilities, ending balance	20,679	4,051
Net deferred tax liabilities	¥ 20,028	¥ 3,400	$ 2,772

Income Taxes - Group's deferr_2

Income Taxes - Group's deferred tax assets (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Income Taxes
Tax loss carry forward	¥ 51,373	$ 7,110	¥ 17,094
Net operating losses acquired through Acquisition	50,821	7,033	16,259
Others	588	82	324
Less, valuation allowance	(101,406)	(14,034)	(32,301)	¥ (12,271)
Balance as of June 30, 2023	1,376	191	1,376
Net deferred tax assets as of June 30, 2023	¥ 725	$ 100	¥ 725

Income Taxes - Group's deferr_3

Income Taxes - Group's deferred tax assets valuation allowance (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)
Income Taxes
Beginning balance	¥ 32,301		¥ 12,271
Increase during the year	19,635		4,769
Increase due to acquisition of entities	50,821		15,206
Decrease due to NOL expiration	(1,558)
Exchange translation adjustment	207		55
Ending balance	¥ 101,406	$ 14,034	¥ 32,301

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - CNY (¥) ¥ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax and Tax Rate
Valuation allowance in a net amount	¥ 70,456	¥ 19,975
Withholding tax rate	10%
PRC
Income Tax and Tax Rate
Net operating loss carryforwards	¥ 404,934	112,370
HK
Income Tax and Tax Rate
Net operating loss carryforwards	¥ 2,325	¥ 30,965

Redeemable noncontrolling int_2

Redeemable noncontrolling interest (Details) ¥ / shares in Units, ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥) ¥ / shares	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2021 USD ($)	Jun. 30, 2023 USD ($)
Redeemable Noncontrolling Interest
Net revenues	¥ 2,091,757	$ 301,280	¥ 1,942,113	$ 300,786	¥ 1,834,422	$ 277,107
Annual net income	(9,611)	$ (1,384)
Actual financing amount	100,931						$ 13,968
Grand Doctor Medical Co., Ltd
Redeemable Noncontrolling Interest
Net revenues	50,000
Annual net income	¥ 6,000
Minority interest (per shares) | ¥ / shares	¥ 1.4
Minority interest period	30 days	30 days
Grand Doctor Medical Co., Ltd | Maximum | Hainan Mingyimingzhen Medical Technology Co., Ltd [Member]
Redeemable Noncontrolling Interest
Payment to third party	¥ 100,000
Actual financing amount	¥ 10,000

Equity (Details)

Equity (Details) $ / shares in Units, ¥ in Thousands, $ in Thousands		1 Months Ended	12 Months Ended
	Mar. 26, 2021 $ / shares shares	Sep. 30, 2022 CNY (¥)	Jun. 30, 2023 CNY (¥) shares	Jun. 30, 2023 USD ($) shares	Sep. 01, 2022	Jun. 30, 2022 CNY (¥) shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2020 USD ($) shares
Ordinary shares, issued shares | shares			56,000,000	56,000,000		56,000,000	56,000,000	50,000,000
Ordinary shares value			¥ 36	$ 5		¥ 36	$ 6	$ 5
Contribution from noncontrolling shareholders | ¥			3,500
Sincerity and Compassion Health Management Center
Equity interest purchased					65%
Additional capital investment to be made by entity | ¥		¥ 6,500
Additional capital investment to be made by minority shareholders | ¥			¥ 68
Contribution from noncontrolling shareholders | ¥		¥ 3,500
Sincerity and Compassion Health Management Center | Sincerity and Compassion Health Management Center
Equity interest held by entity		65%
Equity interest held by minority shareholders		35%
ADS
Number of ordinary shares per ADS | shares	2
IPO | ADS
Number of American depository shares issued | shares	3,000,000
ADS price per share | $ / shares	$ 10
Number of ordinary shares per ADS | shares	2

Earnings Per Share (Details)

Earnings Per Share (Details) ¥ / shares in Units, $ / shares in Units, ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥) ¥ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 CNY (¥) ¥ / shares shares	Jun. 30, 2021 CNY (¥) ¥ / shares shares
Numerator:
Net income attributable to shareholders of Hywin Holdings Ltd.	¥ 129,881	$ 18,707	¥ 235,869	¥ 207,657
Weighted average number outstanding:
Weighted average number outstanding - Basic	56,000	56,000	56,000	51,528
Dilutive effect of outstanding share options	1,972	1,972	1,980	1,992
Weighted average number outstanding - Diluted	57,972	57,972	57,980	53,520
Earnings per share - Basic | (per share)	¥ 2.32	$ 0.33	¥ 4.21	¥ 4.03
Earnings per share - diluted | (per share)	¥ 2.24	$ 0.32	¥ 4.07	¥ 3.88
ADS
Weighted average number outstanding:
Weighted average number outstanding - Basic	28,000,000	28,000,000	28,000,000	25,789,041
Weighted average number outstanding - Diluted	28,986,236	28,986,236	28,989,752	26,773,582
Earnings per share - Basic | (per share)	¥ 4.64	$ 0.67	¥ 8.42	¥ 8.05
Earnings per share - diluted | (per share)	¥ 4.48	$ 0.65	¥ 8.14	¥ 7.76

Restricted Net Assets (Details)

Restricted Net Assets (Details) - CNY (¥) ¥ in Thousands	Jun. 30, 2023	Jun. 30, 2022
Restricted Net Assets
Minimum percentage of after-tax profit transferred by VIEs to general statutory reserve fund	10%
Maximum percentage criteria for appropriation of after-tax profit of Chinese subsidiaries to general reserve fund	50%
Minimum percentage of after-tax profit transferred by domestic enterprise to statutory reserve fund	10%
Maximum percentage criteria for in appropriation of after-tax profit by domestic enterprise to certain statutory reserve funds	50%
Net assets subject to restriction	¥ 473,369	¥ 440,723

Restricted Net Assets - Balance

Restricted Net Assets - Balance Sheets (Details) $ / shares in Units, ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥) shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 CNY (¥) shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2020 USD ($) shares
Assets
Total Assets	¥ 2,373,492	$ 328,475	¥ 1,783,412	$ 265,729
Equity:
Ordinary shares (US$0.0001 par value; authorized 500,000,000 shares; issued and outstanding 56,000,000* shares as of June 30, 2022 and 2023, respectively)	36	5	36		$ 6	$ 5
Additional paid-in capital	515,665	71,364	510,390
Accumulated gain	451,013	62,417	348,503
Accumulated other comprehensive income	16,680	2,309	8,458
Total equity attributable to the shareholders of Hywin Holdings Ltd.	1,111,691	153,850	968,313
Total Liabilities, Mezzanine equity, and equity	¥ 2,373,492	$ 328,475	¥ 1,783,412
Ordinary shares, par value | $ / shares		$ 0.0001		$ 0.0001
Ordinary shares, authorized	500,000,000	500,000,000	500,000,000	500,000,000
Ordinary shares, issued shares	56,000,000	56,000,000	56,000,000	56,000,000	56,000,000	50,000,000
Ordinary shares, outstanding shares	56,000,000	56,000,000	56,000,000	56,000,000
Parent Company
Assets
Investments in subsidiaries and VIEs	¥ 1,111,691	$ 153,850	¥ 968,313
Total Assets	1,111,691	153,850	968,313
Equity:
Ordinary shares (US$0.0001 par value; authorized 500,000,000 shares; issued and outstanding 56,000,000* shares as of June 30, 2022 and 2023, respectively)	36	5	36
Additional paid-in capital	515,665	71,364	510,390
Accumulated gain	579,310	80,172	449,429
Accumulated other comprehensive income	16,680	2,309	8,458
Total equity attributable to the shareholders of Hywin Holdings Ltd.	1,111,691	153,850	968,313
Total Liabilities, Mezzanine equity, and equity	¥ 1,111,691	$ 153,850	¥ 968,313
Ordinary shares, par value | $ / shares		$ 0.0001		$ 0.0001
Ordinary shares, authorized	500,000,000	500,000,000	500,000,000	500,000,000
Ordinary shares, issued shares	56,000,000	56,000,000	56,000,000	56,000,000
Ordinary shares, outstanding shares	56,000,000	56,000,000	56,000,000	56,000,000

Restricted Net Assets - Stateme

Restricted Net Assets - Statements of Operations (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Restricted Net Assets
Net income attributable to shareholders of Hywin Holdings Ltd.	¥ 129,881	$ 18,707	¥ 235,869	¥ 207,657
Parent Company
Restricted Net Assets
Share of income from subsidiaries and VIEs	129,881	18,707	235,869	207,657
Net income attributable to shareholders of Hywin Holdings Ltd.	¥ 129,881	$ 18,707	¥ 235,869	¥ 207,657

Restricted Net Assets - State_2

Restricted Net Assets - Statements of Cash Flows (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Restricted Net Assets
Cash flows from operating activities	¥ 525,322	$ 75,663	¥ 238,751	¥ 334,033
Cash flows from investing activities	(248,665)	(35,816)	(286,497)	(14,631)
Proceeds from issuance of ordinary shares from IPO				180,677
Cash flows from financing activities	1,568	226	(1,000)	185,606
Effect of exchange rate changes	7,280	(7,565)	3,814	11,917
Net change in cash and cash equivalents	285,505	32,508	(44,932)	516,925
Cash, cash equivalents, and restricted cash at beginning of the year	660,378	98,396	705,310
Cash, cash equivalents, and restricted cash at end of the year	945,883	130,904	660,378	705,310
Parent Company
Restricted Net Assets
Interest income	93	13	791
Cash flows from operating activities	93	13	791
Investment in subsidiaries				(180,677)
Cash flows from investing activities				(180,677)
Proceeds from issuance of ordinary shares from IPO				180,677
Cash flows from financing activities				¥ 180,677
Effect of exchange rate changes	64
Net change in cash and cash equivalents	157	13	791
Cash, cash equivalents, and restricted cash at beginning of the year	791	118
Cash, cash equivalents, and restricted cash at end of the year	¥ 948	$ 131	¥ 791

Concentration of Risk (Details)

Concentration of Risk (Details) - Customer concentrations	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Revenue | Customer A
Concentration of Risk
Concentration risk (as a percent)			18%
Revenue | Customer B
Concentration of Risk
Concentration risk (as a percent)			11%
Revenue | Customer C
Concentration of Risk
Concentration risk (as a percent)		13%
Revenue | Customer D
Concentration of Risk
Concentration risk (as a percent)	18%	14%
Revenue | Customer E
Concentration of Risk
Concentration risk (as a percent)	22%	10%
Revenue | Customer G
Concentration of Risk
Concentration risk (as a percent)	16%
Accounts receivable | Customer D
Concentration of Risk
Concentration risk (as a percent)		13%
Accounts receivable | Customer E
Concentration of Risk
Concentration risk (as a percent)		36%
Accounts receivable | Customer F
Concentration of Risk
Concentration risk (as a percent)		12%
Accounts receivable | Customer H
Concentration of Risk
Concentration risk (as a percent)	15%

Employee Defined Contribution_2

Employee Defined Contribution Plan (Details) - CNY (¥) ¥ in Thousands	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Employee Defined Contribution Plan
Employee benefit expenses	¥ 100,338	¥ 73,694	¥ 47,362

Related Party Balances and Tr_3

Related Party Balances and Transactions (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)
Related Party Balances and Transactions
Due from related parties			¥ 66,103
Due to related parties	¥ 38,073	$ 5,269	36,172
Related Party
Related Party Balances and Transactions
Due from related parties			66,103
Due to related parties	38,073	5,269	36,172
Amounts lent | Hywin Financial Holding Group Co., Ltd. | Related Party
Related Party Balances and Transactions
Due from related parties			66,103
Loans Borrowed And Interest Payable
Related Party Balances and Transactions
Due to related parties	15,573	2,155	13,672
Loans Borrowed And Interest Payable | Others | Related Party
Related Party Balances and Transactions
Due to related parties	407	57	406
Loans Borrowed And Interest Payable | Ms. Wang Dian | Related Party
Related Party Balances and Transactions
Due to related parties	1,891	262	1,891
Loans Borrowed And Interest Payable | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I | Related Party
Related Party Balances and Transactions
Due to related parties	5,401	747	5,005
Loans Borrowed And Interest Payable | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II | Related Party
Related Party Balances and Transactions
Due to related parties	6,874	951	6,370
Loans Borrowed And Interest Payable | Beijing Boyi Kangsheng Investment Consulting Co., Ltd | Related Party
Related Party Balances and Transactions
Due to related parties	1,000	138
Dividend payable | Ms. Wang Dian | Related Party
Related Party Balances and Transactions
Due to related parties	¥ 22,500	$ 3,114	¥ 22,500

Related Party Balances and Tr_4

Related Party Balances and Transactions - Summarized by nature (Details) ¥ in Thousands, $ in Thousands			12 Months Ended
	Aug. 25, 2022 CNY (¥)	Jan. 27, 2022 CNY (¥)	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2021 CNY (¥)
Grand Doctor Medical Co., Ltd
Related Party Balances and Transactions
Equity interest acquired		65.26%
Aggregate purchase consideration		¥ 80,500
Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I and Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II | Loans Borrowed And Interest Payable | Grand Doctor Medical Co., Ltd
Related Party Balances and Transactions
Amount of transaction		¥ 10,000
Interest rate on loans borrowed		9%
Related Party | Wealth management and asset management services
Related Party Balances and Transactions
Amount of transaction			¥ 1,679	$ 241	¥ 4,499	¥ 3,144
Related Party | Rental expenses
Related Party Balances and Transactions
Amount of transaction						1,579
Related Party | Collection of loans lent to related parties
Related Party Balances and Transactions
Amount of transaction			66,103	9,521	60,000
Related Party | Loans borrowed from related parties
Related Party Balances and Transactions
Amount of transaction						321
Related Party | Interest payable | Grand Doctor Medical Co., Ltd
Related Party Balances and Transactions
Amount of transaction					11,000
Related Party | Interest Expense
Related Party Balances and Transactions
Interest expenses charged by related parties			900	130	375
Related Party | Hywin Asset Management Co., , Ltd. | Wealth management and asset management services
Related Party Balances and Transactions
Amount of transaction			1,679	241	4,499	3,144
Related Party | Hywin Financial Holding Group Co., Ltd. | Rental expenses
Related Party Balances and Transactions
Amount of transaction						1,579
Related Party | Hywin Financial Holding Group Co., Ltd. | Collection of loans lent to related parties
Related Party Balances and Transactions
Amount of transaction			66,103	9,521	60,000
Related Party | Others | Loans borrowed from related parties
Related Party Balances and Transactions
Amount of transaction						¥ 321
Related Party | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I | Interest payable | Grand Doctor Medical Co., Ltd
Related Party Balances and Transactions
Amount of transaction					4,840
Related Party | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I | Interest Expense
Related Party Balances and Transactions
Interest expenses charged by related parties			396	57	165
Related Party | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II | Interest payable | Grand Doctor Medical Co., Ltd
Related Party Balances and Transactions
Amount of transaction					6,160
Related Party | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II | Interest Expense
Related Party Balances and Transactions
Interest expenses charged by related parties			504	73	¥ 210
Related Party | Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase I and Chongqing Jinpu Medical Healthy Service Private Equity Fund Phase II | Loans Borrowed And Interest Payable | Grand Doctor Medical Co., Ltd
Related Party Balances and Transactions
Equity interest acquired		65.26%
Related Party | Life Infinity | Repayment of loans borrowed from related parties | Beijing iLife 3 Technology Co., Ltd.
Related Party Balances and Transactions
Amount of transaction	¥ 1,000
Equity interest acquired	63.39%
Aggregate purchase consideration	¥ 141,232
Related Party | Life Infinity | Interest Expense
Related Party Balances and Transactions
Amount of transaction			1,000	144
Interest expenses charged by related parties			¥ 1,000	$ 144

Share-based Compensation (Detai

Share-based Compensation (Details) ¥ / shares in Units, ¥ in Thousands

12 Months Ended

Mar. 26, 2021 $ / shares shares

Oct. 01, 2019 shares

Sep. 30, 2019 CNY (¥) $ / shares shares

Jan. 08, 2018 ¥ / shares shares

Jan. 08, 2018 $ / shares shares

Jan. 01, 2017 ¥ / shares shares

Jan. 01, 2017 $ / shares shares

Jan. 01, 2016 ¥ / shares shares

Jan. 01, 2016 $ / shares shares

Jun. 30, 2023 shares

Jun. 30, 2021 shares

Jun. 30, 2022 shares

Share-based Compensation

Exercisable options (in shares)

946,897

781,270

2018 Option Plan

Share-based Compensation

Options granted and issued

750,247

Share options, exercise price | $ / shares

$ 16.43

Share-based compensation liabilities | ¥

¥ 6,560

2018 Option Plan | Hywin Wealth Management Co., Ltd.

Share-based Compensation

Options granted and issued

8,998,465

8,998,465

8,998,465

8,998,465

8,998,465

8,998,465

Share options, exercise price | ¥ / shares

¥ 1.83

¥ 1.35

¥ 1.23

2019 Option Plan

Share-based Compensation

Options granted and issued

1,499,753

0

2,250,000

Threshold period for exercise of options after the IPO

5 years

Requisite service period

1 year

5 years

Exercisable options (in shares)

1,883,803

1,912,303

2019 Option Plan | Hywin Wealth Management Co., Ltd.

Share-based Compensation

Options granted and issued

1,499,753

Share options, exercise price | $ / shares

¥ 0

$ 2.801

$ 1.946

$ 1.894

Maximum number of ordinary shares available for issuance

2,250,000

Number of Hywin Wealth Management's options replaced with each option under the Company's plan

10

Threshold period for exercise of options after the IPO

1 year

Share-based Compensation - Weig

Share-based Compensation - Weighted Average (Details) - $ / shares			12 Months Ended
	Mar. 26, 2021	Oct. 01, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Exercisable, Ending			946,897	781,270
2018 Option Plan
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Granted/Vested	750,247
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life, Granted/Vested	1 year 1 month 9 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, granted/vested	$ 16.43
2019 Option Plan
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding and exercisable, beginning				2,014,387
Granted/Vested	1,499,753	0			2,250,000
Forfeited			(28,500)	(102,084)	(235,613)
Outstanding and exercisable, Ending					2,014,387
Exercisable, Ending			1,883,803	1,912,303
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life, outstanding and exercisable			1 month 24 days	7 months 13 days	1 year 5 months 23 days
Weighted Average Remaining Contractual Life, Granted/Vested	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted Average Exercise Price, outstanding and exercisable beginning			$ 5.02	$ 5.29
Weighted Average Exercise Price, forfeited			1.27	1.21	$ 0.74
Weighted Average Exercise Price, outstanding and exercisable ending			$ 5.03	$ 5.02	$ 5.29

Share-based Compensation - Opti

Share-based Compensation - Options (Details) - CNY (¥) ¥ in Thousands			12 Months Ended
	Mar. 26, 2021	Oct. 01, 2019	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation
Total unrecognized compensation cost			¥ 725
Unrecognized compensation costs expected to be recognized over a weighted average period			1 month 24 days
2018 Option Plan
Share-based Compensation
Options granted and issued	750,247
2019 Option Plan
Share-based Compensation
Options granted and issued	1,499,753	0			2,250,000
Share-based compensation expenses			¥ 5,207	¥ 7,340	¥ 21,947

Segment information (Details)

Segment information (Details) ¥ in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 CNY (¥)	Jun. 30, 2021 USD ($)
Segment information
Total net revenues	¥ 2,091,757	$ 301,280	¥ 1,942,113	$ 300,786	¥ 1,834,422	$ 277,107
Income from operations	197,385	28,430	326,690	50,596	281,606	42,539
Net income/(loss)	120,270	$ 17,323	235,869	$ 36,530	207,657	$ 31,369
Operating segments | Wealth Segment
Segment information
Total net revenues	2,005,293		1,941,691		1,834,422
Income from operations	308,530		337,775		281,606
Net income/(loss)	231,419		247,359		¥ 207,657
Operating segments | Health Segment
Segment information
Total net revenues	87,841		422
Income from operations	(111,145)		(11,085)
Net income/(loss)	(111,149)		¥ (11,490)
Eliminated
Segment information
Total net revenues	¥ (1,377)

Segment information - Assets (D

Segment information - Assets (Details) ¥ in Thousands, $ in Thousands	Jun. 30, 2023 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 CNY (¥)	Jun. 30, 2022 USD ($)
Segment information
Goodwill	¥ 257,712	$ 35,666	¥ 75,194	$ 11,204
Other assets	2,115,780	292,809	1,708,218	254,525
Total Assets	2,373,492	$ 328,475	1,783,412	$ 265,729
Operating segments | Wealth Segment
Segment information
Other assets	2,154,194		1,665,803
Total Assets	2,154,194		1,665,803
Operating segments | Health Segment
Segment information
Goodwill	257,712		75,194
Other assets	296,324		42,415
Total Assets	554,036		¥ 117,609
Eliminated
Segment information
Other assets	(334,738)
Total Assets	¥ (334,738)

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Events ¥ in Thousands	1 Months Ended
	Sep. 30, 2023 CNY (¥) m²
Subsequent Events
Total site area | m²	56,449.39
Consideration | ¥	¥ 129,200